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ABSTRACT
Cytotoxicity of Novel Cisplatin Analogs in Lung, Prostate 
and Breast Cancer Cells
by
Van Vo
Dr. Stephen W. Carper, Examination Committee Chair 
Professor of Chemistry 
University of Nevada, Las Vegas
The antitumor agent that is most prescribed for the treatment of cancer is cis- 
diamminedichloroplatinum (II) (cisplatin), but its application is limited due to toxic side 
effects; especially nephrotoxicity. Due to these limitations, numerous analogs have been 
developed. The cytotoxicity of five novel cisplatin analogs, dichloro(4,4'-diethyl-2,2'- 
bipyridine)platinum, dichIoro(4,4'-dipropyl-2,2'-bipyridine)platinum, dichloro(4,4'-di-t- 
butyl-2,2'-bipyridine)platinum, dichloro(4,4'-dimethoxy-2,2'-bipyridine)platinum and 
dichloro[4,4'-bis(3-methoxypropyl)-2,2'-bipyridine]platinum, in lung (A549), prostate 
(DU-145) and five breast (MCF-7, MDA-MB-435, MDA-MB-231, DC4 and DB46) 
cancer cell lines were investigated. Clonogenic survivals demonstrated that these novel 
analogs were 47 to 242 times more lethal than cisplatin and killed cells predominately by 
apoptosis. The analogs did not typically cause a block in the cell cycle. Results from 
clonogenic survivals and calculation of the combination index (Cl) revealed that several 
analogs had slightly synergistic interactions with ionizing radiation to kill prostate and
111
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breast cancer cell lines. Results indicate that these novel analogs may be potential 
antitumor agents in clinical treatment.
IV
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CHAPTER 1
INTRODUCTION
1.1 Background and Significance 
Cancer is a wide range of diseases associated with abnormal and uncontrolled cell 
division. It is one of the leading causes of death in the United States and for the 
American population, it is estimated that one in two men and one in three women will 
develop some type of cancer within their lifetime. As reported by the American Cancer 
Society, with approximately 554,000 deaths in 2004, cancer accounted for 23% of all 
deaths in the United States (U.S) only falling behind to heart diseases. For 2007, it is 
estimated that there will be 289,550 cancer deaths in men with 31% due to lung cancer 
and 9% due to prostate cancer; whereas 270,100 cancer deaths is estimated for women 
with 26% due to lung cancer and 15% due to breast cancer. Furthermore, almost 1.4 
million new cases of cancer will be diagnosed for the U.S. population in 2007, with men 
having 766,860 cases and 678,060 cases in women. Opposite to the percent of deaths 
estimated, the majority of the new cancer cases in men will be prostate (29%) followed 
by lung (15%); for women 26% of the new cases will be breast cancer and 15% will be 
lung cancer.
Many treatment modalities are available for cancer; however, the three most 
common are surgery, radiotherapy and chemotherapy. Surgery is usually the first
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approach to treatment and is very successful for some cancers; however, surgery is not 
appropriate for all cancers, such as metastasizing cancer like leukemia. Also, for those 
cancers in which surgery is suitable it is often difficult to remove all of the diseased cells 
because of the limit of detection of current technologies.
Radiation therapy (radiotherapy) has proven to be effective in the treatment of 
solid tumors, leukemia and lymphoma (Tobias, 1992). Radiotherapy works by the use of 
ionizing radiation (IR) which damages DNA, either by directly hitting DNA or, more 
commonly, by formation of free radicals through interactions, with water which then 
interacts with DNA (Fang et al., 2002). Damage to DNA caused by radiation leads to 
cell death either through apoptosis (programmed cell death) or through inhibition of 
cellular division and proliferation (Kerr et al., 1994; Ross, 1999). Radiotherapy offers 
advantages over surgery in that there is no surgical risk and although it does not 
selectively kill cancer cells, treatment could be localized to one particular area.
Chemotherapy is also widely used in the treatment of cancer. Countless 
chemotherapeutic agents have been identified and are currently used for clinical 
treatments; cis-diamminedichloroplatinum (II) (cisplatin or CDDP) is one of these agents. 
Cisplatin was first synthesized by Peyrone in 1844 and Barnett Rosenberg accidentally 
discovered its antitumoral property in 1965 (Wozniak and Blasiak, 2002; Liedert et al., 
2006). It was then approved by the FDA for clinical treatment in 1978 and is now widely 
used in the treatment of many malignancies, including glioblastoma multiforme, 
epidermoid carcinomas of the head and neck, cancers of the bladder, lung, breast, uterus 
and cervix, and testicular cancer (Jamieson and Lippard, 1999; Furuta et al., 2002; Min et 
al., 2005).
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A plethora of data on cisplatin has been published; however, the precise 
mechanism of action is not yet known. The cytotoxic effect of cisplatin is believed to be 
due to the formation of DNA adducts. Once administered into the body, cisplatin is kept 
inactivated by the high chloride ion concentration in the extracellular space. It is 
activated by passing through the plasma membrane (it is not known whether this is 
through passive diffusion or with the help of a transporter protein) into the cell where the 
low chloride ion concentration allows cisplatin to substitute the chloride ions with water 
molecules and nucleophilic attack at the N7 position of guanine and adenine (one 
chloride ion at a time) (Lemaire, 1991; Jamieson and Lippard, 1999; Wozniak and 
Blasiak, 2002; Diggle et al., 2005; Liedert et al., 2006). Formation of the cisplatin-DNA 
cross-links distort the DNA double helix, leading to unwinding and kinking of the DNA 
(Jamieson and Lippard, 1999; Wozniak and Blasiak, 2002). This prevents effective 
repair of the DNA leading to inhibition of DNA replication and transcription and 
ultimately death (Jamieson and Lippard, 1999; Furuta et al., 2002). Additionally, 
cisplatin can also bind to proteins important for DNA replication and cell division; 
however, the primary target is DNA.
Because displacement of the chloride ions and nucleophilic attack of cisplatin to 
DNA occurs one at a time cisplatin can, therefore, form monofimctional and bifunctional, 
interstrand and intrastrand cross-links, adducts with DNA. In order to form bifunctional 
adducts, the two DNA bases cannot be more than one base apart. The major forms of 
cross-links are the 1, 2-intrastrand cross-links, which contribute the most to cytotoxic 
effects (Huang et al., 1995, Takahara et al., 1996). Formation of adducts causes 
unwinding and a high degree of bending toward the major groove; although the overall
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structure of the DNA double helix stays the same, the arrangement of several bases are 
disrupted (Huang et al., 1995, Takahara er al., 1996). Damage of DNA by cisplatin 
causes activation of cellular repair mechanisms. Nucleotide excision repair (removes the 
damaged base) and mismatched repair (removes a section of damaged DNA) have been 
implicated in the repair of cisplatin damaged DNA and thus play a role in the sensitivity 
or resistance of the cells to cisplatin (Van Houten, 1990; Calsou et al., 1992; Hansen and 
Kelly, 2000, Sancar et al., 2004).
Although cisplatin is one of the most effective and most prescribed antitumor 
agents today, its application is limited. Limitations of the drug include cellular resistance 
to platinum, the toxic side effects (renal toxicity, emesis, neurotoxicity, bone marrow 
suppression and hearing loss) (Wood and Hrushesky, 1995; Furuta et al., 2002; Liedert et 
al., 2006) and its limited spectrum of activity against all types of cancer. Resistance to 
cisplatin is often associated with various biological processes such as inactivation of the 
drug, an increase in antiapoptotic proteins, DNA damage/repair proteins, retention of the 
drug (i.e. increased influx or decreased uptake), and growth signaling via different 
pathways (Furuta et al., 2002; Wu et al., 2005). As a consequence of the limitations of 
cisplatin, numerous analogs have been developed and characterized with the goal of 
finding compounds that could be more effective and have less toxicity; some were found 
to be more effective, while others were less effective (Marini et al., 2005; Abdullah et al., 
2006).
Recently, several novel cisplatin analogs [dichloro(4,4'-diethyl-2,2'- 
bipyridine)platinum (diethyl or DEt), dichloro(4,4'-dipropyl-2,2'-bipyridine)platinum 
(dipropyl or DP), dichloro(4,4'-di-t-butyl-2,2'-bipyridine)platinum (4 tertbutyl or 4TB),
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dichloro(4,4'-dimethoxy-2,2'-bipyridine)platinum (new diether or NDE) and 
dichloro[4,4'-bis(3-methoxypropyl)-2,2'-bipyridine]platinum (diether or DE)] containing 
the original cis-platinumdichloride center and a new bipyridine ring structure with 
varying arm lengths at the 4 and 4' positions have been synthesized (Figure 1, page 10) 
(Karayusuf, 2007). The cytotoxicity of these novel analogs (Figure 1) and that of 
dichloro(4,4'-dibutyl-2,2'-bipyridine)platinum (dibutyl or DB) (an analog in which the 
cytotoxicity have not been reported) was determined with clonogenic survival for cell 
lines of the three most common types of cancer in men and women [lung (A549), prostate 
(DU-145), breast (MCF-7, MDA-MB-435, MDA-MB-231, DC4 and DB46)] and its 
potency compared to that of cisplatin and the analog dichloro(2,2'-bipyridine)platinum 
(Bipyridine or BP), the structure from which the arms of the new analogs were added. 
With a more bulky structure compared to cisplatin and BP, these analogs are likely to be 
more effective in treating the various cancer cell lines and can potentially be used as 
antitumor agents in clinical treatment.
Although cisplatin and radiation therapy are quite effective as individual agents in 
the treatment of cancer, they are often used concurrently to increase the effectiveness of 
treatment. The effects of the combination of cisplatin and ionizing radiation have been 
published in numerous articles and in many cases the findings are conflicting with each 
other. Several articles report a synergistic interaction between cisplatin and radiation, 
while others report only additive or even antagonist interactions (Stewart et al., 1994; 
Lawrence et al., 2003; Fehlauer et al., 2005; Rave-Frank et al., 2007). Although data 
regarding the interactions of cisplatin and radiation is inconclusive, it is possible that the 
novel analogs will provide better interactions with radiation. Clonogenic survival assays
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will be performed to study the interaction of cisplatin and the analogs 4TB, DB, and DE 
with ionizing radiation in A549, DU-145, MCF-7, MDA-MB-435 and MDA-MB-231 
cell lines. Calculation of the combination index (Cl) will quantitatively determine 
whether the interactions are synergistic, additive or antagonistic.
In addition to cytotoxicity and possible interactions with IR, a possible 
mechanism of cell death was also investigated. It is generally known that cell death 
occurs by two processes, necrosis or apoptosis (Manjo and Joris, 1995; Thomson, 1995). 
Necrosis is a type of programmed cell death due to injury. Necrosis does not involve cell 
signaling and is often accompanied by the release of cellular contents containing enzymes 
which can digest components of the cell. Apoptosis is a regulated process of 
programmed cell death that is activated by biological signaling events (Manjo and Joris, 
1995; Thomson, 1995). Some characteristics of apoptosis are flipping of the 
phospholipid phosphatidyl serine to the outer surface of the plasma membrane (an early 
event), cell shrinkage, release of cytochrome c, formation of apoptotic bodies, and 
fragmentation of DNA (Manjo and Joris, 1995; Thompson, 1995).
Flow cytometry was used to examine the distribution of DNA content in the cell 
cycle and to observe apoptosis in A549, DU-145 and MDA-MB-435 cells treated with: 
BP, 4TB, DEt, DP, DB, NDA and DE for 1 hour. Cell cycle distribution and apoptosis 
was also investigated for MCF-7 and MDA-MB-231 cells treated with 4TB, DB and DE. 
Flow cytometry is a method used to determine the physical and chemical characteristic of 
a single cell. Characteristic light scattering, light excitation and emission of 
fluorochrome molecules are used to obtain information about a cell. To determine cell 
cycle distribution and level of apoptosis, the DNA content was measured using the
R ep ro d u ced  with p erm issio n  o f  th e  copyrigh t ow n er. Further reproduction  prohibited w ithout p erm ission .
fluorochrome molecule, propidium iodide (PI). PI is a stain that is impermeable to the 
membrane and is excluded from live cells, thus, PI is commonly used to identify dead 
cells. In order to measure the DNA content of live cells, the cells are treated with Triton 
X-100, which is a detergent that allows PI to be taken up by the cell. PI can readily 
intercalate into DNA and the fluorescence can then be measured. The intensity of the PI 
is proportional to DNA content, which indicates at which phase of the cell cycle the cell 
is in (based on the ploidy of the cell).
During development cells usually go through a cycle of resting stage (interphase) 
and division stage (mitosis or M phase). The resting stage or interphase can generally be 
divided into four parts: Gap 0 (GO), Gap 1 (Gl), synthesis phase (S) and Gap 2 (G2). 
Cells in the GO phase are known to be quiescent; they are no longer dividing and are not 
part of the cell cycle. Cells in this phase can either return to the cell cycle or stay there 
permanently. Gl is the first phase of interphase and is known to be a stage of cell 
growth. Cells in this stage are actively producing RNA and synthesizing proteins in 
preparation for cell division. The ploidy of cells in this phase is IN. The Gl phase 
contains a cell cycle check point that determines if the cell is big enough to go on to the S 
phase. The S phase is the next step in interphase and is the stage in which DNA synthesis 
occurs. As the cells are still in the process of DNA synthesis, their ploidy is still IN. The 
G2 phase follows synthesis and is a stage in which the cell continues to grow and produce 
proteins. The ploidy of cells in this phase is 2N. At the end of G2 phase is a check point 
to determine if the cell is big enough, if the DNA has replicated and if the environment is 
suitable for the cell to start dividing. Finally, the last step that occurs before the cell 
cycle is repeated is the mitosis (M) phase. At the M phase cell growth has stopped and
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the cell goes through the process of dividing into two daughter cells. At this stage the 
ploidy of the cell is still 2N and cannot be differentiated with the G2 phase by flow 
cytometry.
For MDA-MB-435 cells treated with EC50 concentration of cisplatin and the 
various analogs, Annexin V staining was also used to evaluate the percent of cells 
undergoing apoptosis versus necrosis. Annexin V is a stain that detects the flipping of 
phosphatidyl serine to the outer surface of the plasma membrane, an event that happens 
early in apoptosis (Bratton et al., 1999). For flow analysis of cell death, Annexin V is 
conjugated to an FITC label and cells are simultaneously stained with PI. Cells that are 
dead (necrotic) or are undergoing late apoptosis will be stained with PI, Annexin V will 
stain early apoptotic cells and cells that stain positive for both Annexin V and PI are late 
apoptotic cells. The percent of late apoptotic cells is added to the percent of early 
apoptotic cells and is eompared to the percent of necrotic cells.
DNA laddering was done to observe apoptosis for MDA-MB-435 treated for 1 
hour with EC50 concentration of cisplatin and the analogs. DNA was extracted 24 hours 
after treatment and separated by agarose gel electrophoresis. As cells undergo apoptosis, 
DNA fragmentation occurs. Observation of DNA laddering or a smear on the agarose gel 
indicates apoptosis.
Fluorescent microscopy was used to investigate the mechanism of cell death in 
MCF-7 cells 48 hours after a 1 hour treatment with EC50 concentration or the highest 
concentration used in clonogenic survival of BP, 4TB and DB. The purpose of 
fluorescent microscopy was to confirm the results obtained in the clonogenic survival 
assays and flow cytometry. For fluorescent microscopy analysis, the cells were stained
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with Hoechst and PI. PI, as described earlier, will only stain cells in which the membrane 
is not intact. Hoechst dye will bind to DNA and provide information regarding 
chromatin condensation, a eharacteristic of early apoptosis.
1.2 Hypothesis
Five novel cisplatin analogs, each containing a bipyridine ring structure with 
varying arm length at the 4 and 4' positions will be more effeetive than cisplatin in 
treating lung (A549), prostate (DU-145) and breast (MCF-7, MDA-MB-435, MDA-MB- 
231, DC4 and DB46) cancer cells. Also, the analogs will have synergistic interactions 
with ionizing radiation.
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HgN Cl
H3N Cl
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(C isp la tin  or C D D P )
Dichloro(2,2'-bipyridine)platinum  
(Bipyridine or BP)
/  \
Dichloro(4,4'-diethyl-2,2'-bipyridine)platinum
{Diethyl or DEt)
Dichloro(4,4’-diprq)yl-2,2'-bipyridine)platinum 
(Dipropyl or DP)
/  \
Dichloro(4,4'-dibutyl-2,2'-bipyridine)platinum 
(Dibutyl or DB)
= N .
/  \
Dichloro(4,4'-dimethoxy-2,2'-bipyridine)platinum 
(New Diether or NDE)
Dichlcro(4,4’-di-t-butyl-2,2'-bipyridine)platinum 
(4-tertbutyl or 4TB)
D ichioro[4,4 '-bis(3-m ethoxypropyl)-2,2’-b ipyrid ine]p latinum  
(D iether or DE)
Figure 1. Structure of Cisplatin and its Analogs. Cisplatin is a clinically used anti-tumor 
agent. BP is a known cisplatin analog. DEt, DP, DB, 4TB, NDE and DE are novel 
cisplatin analogs.
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CHAPTER 2
MATERIALS AND METHODS
2.1 Cell Culture
Human cancer cell lines A549 (lung carcinoma), DU-145 (prostate carcinoma), 
MCF-7 (breast epithelial adenocarcinoma), MDA-MB-435 (breast ductal 
adenocarcinoma) and MDA-MB-231 (breast epithelial adenocarcinoma) were obtained 
from American Culture Type Collection (ATCC). DC46 and DC4 are transformed cells 
derived from MDA-MB-231 cells (Carper et al., 1997). DB46 contains a vector that 
continuously expresses beat shock protein 27 (Hsp27). DC4 also contains the same 
vector as DB46 cells with the exception of the Hsp27 cDNA and only expresses 
endogenous level of Hsp27. A549, MCF-7, MDA-MB-435, MDA-MB-231, DC4 and 
DB46 cells were grown in Minimum Essential Medium (MEM, Invitrogen) 
supplemented with 10% Fetal Bovine Serum (FBS, Invitrogen), Penicillin- Streptomycin 
(P.S., Invitrogen) and 25 mM HEPES buffer (pH 7.4) (Sigma). Also added to the growth 
medium of DC4 and DB46 was G418, an antibiotic which aids in the retention of the 
plasmids, in a ratio of 75 pL of a 40 pg/mL stock solution per 5 mL of MEM. DU-145 
cells were grown in RPMI-1640 (ATCC) with the same supplementation as MEM. Cell 
were washed with Phosphate Buffered Saline (PBS, Invitrogen) and treated with 0.25 % 
Trypsin-EDTA (Invitrogen) to allow for the detachment from plastic surfaces. Cells 
were incubated at 37°C with 5% CO2 environment.
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2.2 Drag Preparation 
Cis-diamminedichloroplatinum (II) (cisplatin) (Sigma) was dissolved in DMSO 
(> 99.9% A.C.S Spectrophotometric grade, Sigma-Aldrich) to obtain a stock solution of 
50 mM and diluted in sterile filtered DMSO for stock concentrations of 5 mM, 0.5 mM, 
0.05 mM and 0.005 mM. Dichloro(2,2'-bipyridine)platinum (bipyridine or BP), 
Dichloro(4,4'-diethyl-2,2'-bipyridine)platinum (diethyl or DEt), Dichloro(4,4'-dipropyl-
2,2 -bipyridine)platinum (dipropyl or DP), Dichloro(4,4'-dibutyl-2,2'-bipyridine)platinum 
(dibutyl or DB), Dichloro(4,4'-di-t-butyl-2,2'-bipyridine)platinum (4 tertbutyl or 4TB), 
Dichloro(4,4'-dimethoxy-2,2'-bipyridine)platinum (new diether or NDE) and 
Dichloro[4,4'-bis(3-methoxypropyl)-2,2'-bipyridine]platinum (diether or DE) 
(synthesized in Dr. Byron L. Bennett’s lab at UNLV) were dissolved in DMSO to obtain 
a stock solution of 5 mM. All solutions were sterile filtered and diluted in sterile filtered 
DMSO to obtain stock solutions of 0.5 mM, 0.05 mM and 0.005 mM.
2.3 Clonogenic Survival Assay 
Semi-confluent cells (40%-80%) were incubated at 37°C with 5% CO2 for 1 hour 
with varying concentrations of cisplatin or its analogs (0, 10' ,^ 10' ,^ 10'^^, 10"^ , lO"'*^ , 10"^  
and 10'  ^M). After 1 hour cells were washed with PBS, trypsinized, fresh medium added 
and counted with Beckman Coulter Z1 Particle Counter. The appropriate numbers of 
cells were then plated in 60 mm dishes containing 4 mL of supplemented media. Cells 
were incubated at 37°C with 5% CO2 for 11-14 days, stained with 0.5% crystal violet 
(Sigma-Aldrich) in 95% ethanol and colonies (a cluster 50 or more cells) were counted. 
Cell survivals of treatment groups were normalized to control (previous experiments
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indicate that the concentration of DMSO used for the treatment groups had no effect on 
cells and thus it was not added to control). For survival assays of DC4 and DB46 the 
media also contained G418 and cells were washed with lOX PBS.
For survival with ionizing radiation (IR), 40%-80% confluent cells were 
irradiated using a Faxitron X-ray set operating at a 24” SID Shelf Position 2, a beam 
diameter of 17.4 inches and 60 kVp which gives a dose rate of 1 Gy/min for 0, 1, 3, 5, 6 
and 7 min. (0, 1, 3, 5, 6 and 7 Gy). After irradiation cells were harvested, counted and 
plated in 60 mm dishes containing 4 mL supplemented media. Cells were incubated at 
37°C with 5% CO2 for 11-14 days, stained with crystal violet and the number of colonies 
was counted. Cell survivals of treatment groups were normalized to control.
Following the procedure as described above, clonogenic survival assays were 
carried out for the combination treatment of drug with IR. 40%-80% confluent cells 
incubated at 37°C with 5% CO2 for 1 hour with cisplatin or its analogs and then 
irradiated with varying IR doses. After treatment cells were harvested, counted and 
plated in 60 mm dishes containing 4 mL supplemented media. Cells were incubated at 
37°C with 5% CO2 for 11-14 days, stained with crystal violet and the number of colonies 
was counted. Cell survivals of treatment groups were normalized to control (no DMSO 
added). Combination index (Cl) values were calculated using the formula Cl = (Di/Dxi) 
+ (D2/DX2), where Dxi is the concentrations of the drug and Dx2 is the IR doses which are 
required to produce an x% survival. Di and D2 are concentrations of drug and IR doses 
in combination which are required to produce the same x% survival as the agents alone. 
Cl values <1 indicates treatments are synergistic. Cl = 1 indicates treatments are additive
13
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and CI > 1 indicates treatments are antagonistic (Pauwels et al., 2006). Cl values were 
plotted against the fraction affected (fa).
2.4 Flow Cytometry
For propidium iodide (PI) staining, 40%-80% confluent cells were incubated at 
37°C with 5% CO2 for 1 hour with EC50 concentration or lO"^  M of cisplatin analogs. 
After one hour, cells were washed with 5 mL PBS and fresh medium added. Cells were 
incubated at 37°C with 5% CO2 for 24 and 48 hours, at which point cells were harvested, 
counted and centrifuged at 500g for 5 minutes. Cells were then washed two times with 5 
mL PBS, with each wash cells were centrifuged at 500g for 5 minutes. After washing, 
cells were fixed by re-suspending in 0.1 mL PBS and 1 mL of cold 95% ethanol was 
slowly added drop wise with gentle vortexing. Fixed cells were incubated at 4°C until 
analysis. For analysis, fixed cells were washed once with 1-2 mL PBS and centrifuged at 
500g for 5 minutes. Cells were re-suspended in 100 pL of 1.0% Triton X-100 buffer 
solution (Sigma). 100 pL of a 1.0 mg/mL RNAse (Sigma) solution was added and 
allowed to stand at room temperature for 10-15 minutes. While in the dark, 200 pL of a 
100 pg/mL PI stain (Sigma-Aldrich) was added to make a final concentration of 50 
pg/mL and gently vortexed. Cell mixture was incubated at room temperature for 30 
minutes. Cytometry acquisition was done by a Becton Dickinson FACS Calibur with 
argon laser set at 488 nm on the linear Flow Channel 2 (FL-2) with Doublet 
Discriminatory Module (DDM) and Threshold set on FL-2.
For Annexin V-FITC/PI staining, the same procedure was used as for PI staining 
up to the washing point before fixation. After harvesting and coimting, cells were
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centrifuged at 500g for 5 minutes and washed once with 5 mL Ca^  ^and Mg^ "^  free PBS. 
Cells were re-suspended in Ix binding buffer (BD Biosciences Pharmingen) at a 
concentration of 1 x 10  ^cells/mL. 100 pL of the solution (1 x 10^  cells) was transferred 
to a 5 mL tube, and 5 pL of Annexin V-FITC (BD Biosciences Pharmingen) and 10 pL 
of PI were then added. Cells were gently vortexed and incubated in the dark at room 
temperature for 15 minutes. 400 pL of Ix binding buffer was added before analysis by 
flow cytometry. For flow cytometry analysis, control cells were divided into three 
groups: unstained cells, cells stained with Annexin V only and cells stained with PI only. 
Treatment cells were stained with both Annexin V and PL AnnexinV was set at FLl and 
PI was set at FL3; threshold was set with FSC at 52 cutoff. Quadrants were assigned 
with single color control staining samples; LL represents negative population (the 
unstained or alive cells), LR represents the cells stained with AnnexinV-FITC only (early 
apoptosis), UL represents the cells stained with PI only (necrosis) and UR represents cells 
stained with both AnnexinV-FITC and PI (late apoptosis). The values of UR and LR 
were added to obtain the percent apoptosis.
2.5 DNA Laddering
Semi-confluent cells (50%-80%) were treated with the EC50 concentration of 
cisplatin or its analogs for 1 hour at 37°C with 5% CO;. After 1 hour, cells were washed 
once with PBS and fresh media added. Cells were then incubated at 37°C with 5% CO2 
for 24 hours. At the appropriate time cells were harvested and counted. 100 pL of lysis 
buffer (lOmM Tris HCl pH 7.4), lOmM EDTA and 0.5% Triton X-100) was added per 1 
X 10^  cells and incubated for 10 minutes at 4°C. Cells were then centrifuged at 13,000
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rpm for 5 minutes, RNAse (1 mg/mL) was added to the supernatant for a final 
concentration of 20 pg/mL and samples were incubated for 1 hour at 37°C. After the 
hour, samples were incubated for 30 minutes at 50°C with proteinase K (1 mg/mL) at a 
final concentration of 20 pg/mL. DNA was precipitated overnight at -20°C following 
the addition of 42mM NaCl (IM  stock) and 50% isopropanol. Samples were centrifuged 
at 13,000 rpm for 15 minutes and the supernatant was removed. The DNA pellet was re­
suspended in 20 pL of TE buffer (lOmM Tris-HCl and ImM EDTA) and a mixture of 10 
pL and 2 pL of a 6x loading dye was run on a 2% agarose gel in TBE buffer (89 mM Tris 
Base, 89 mM Boric acid and 2.6 mM EDTA) at 60 V. The gel was stained with ethidium 
bromide (1 pg/mL). All reagents were from Sigma, except agarose (Carolina Biological).
2.6 Fluorescent Microscopy 
Semi-confluent cells (50%-80%) were harvested, counted and 5,000 or 10,000 
cells per well were plated in a 4 well chamber slide with a final volume of 0.5 mL. Cells 
were incubated at 37°C with 5% CO2 for 72 hours and then treated with EC50 
concentration or the highest concentration used in survival assays of cisplatin analogs for
1 hour at 37°C with 5% CO2 . Cells were washed twice with 0.5 mL PBS and 0.5 mL of 
fresh media was added. Cells were incubated at 37°C with 5% CO2 for 48 hours. While 
in the dark, media was removed, cells were washed with 0.5 mL PBS, and then 0.5 mL of
2 pg/mL Hoechst and lOpg/mL PI stain (in PBS) was added to make a final concentration 
of 1 pg/mL Hoechst and 5 pg/mL PI. Cells were incubated for 15 minutes at room 
temperature. Images were acquired within 5 minutes with a Nikon Eclipse microscope, 
model TE2000-U. Three random areas on each slide were imaged for bright field, cells
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stained with Hoechst and cells stained with PI (9 images were obtained for each slide: 3 
for bright field, 3 for Hoechst staining and 3 for PI staining). The amount of apoptosis 
and necrosis was calculated as a percent of Hoechst positive and PI positive cells as a 
percent of the total cells in the bright field image.
2.7 Statistical Analysis 
GraphPad Prism 4 was used to graph survival curves and to run non-linear 
regressions. ModFit version 3.0 was used for flow cytometry analysis. Microsoft Office 
Excel was used to run one-tailed Student’s t-Test. For comparison of two groups with 
different number of samples, unpaired t-test was used with two samples assuming 
unequal variance and for comparison of two groups with the same number of samples, 
unpaired t-test was used with two samples assuming equal variance. Values with p<0.05 
were considered statistically significant.
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CHAPTER 3
RESULTS AND DISCUSSION
3.1 Clonogenic Survival Assays 
The ability of various cancer cell lines (A549, DU-145, MCF-7, MDA-MB-435, 
MDA-MB-231, DC4 and DB46) to produce daughter cells after I hour treatment with 
cisplatin and its analogs (commercially available BP and novel 4TB, DEt, DP, DB, NDE 
and DE) was assessed with clonogenic survival assays. Cytotoxic effects of cisplatin, 
BP, 4TB, DB and DE were determined for A549 (data for BP not yet available), DU-145, 
MCF-7, MDA-MB-435 and MDA-MB-231. Cytotoxic effects of DEt, DP and NDE 
were also determined for A549, DU-145 and MDA-MB-435. cells. Only cytotoxic effects 
of 4TB, DB and DE were determined for DC4 and DB46 cells.
3.1.1 Cytotoxic effects of cisplatin and its analogs on A549 cells 
For A549 lung cancer cells, cisplatin was used in the final concentrations of 1 x 10’ 
 ^M, IX10'  ^M, 1X10'  ^M and 1X10'  ^M. BP, 4TB, DEt, DP, DB, NDE and DE were used 
in the final concentrations of 1x10’^  M, 1x10’® M, 1x10’^  ^M, IxlQ^ M, IxlO'"*  ^M and 
1X lO"'^  M. Cisplatin had no effect on cell survival at the concentration range of 1 x 10"’ M 
tolxlO'"* M. At the highest concentration used (IxlQ^ M) cell survival was reduced to 
53% (Figure 2, page 35). 4TB and NDE had little effect on A549 survival with 90% and 
82%, respectively, at the highest concentration of IxlQ'"* M (Figure 2, page
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35). A549 had a slight dose response to DB and DEt treatment with 67% and 66% 
survival, respectively, at IxlO'"' M. There was an apparent dose response when cells 
were treated with DP, DB and DE; as the concentration increases, survival rate decreases. 
All three drugs had less than 1% survival at 1x10 '* M (Figure 2, page 35).
3.1.2 Cytotoxic effects of cisplatin and its analogs on DU-145 cells
For DU-145 cells, cisplatin was used in the final concentrations o f 1x10'^ M, 
1x10'^ M, 1x10^ M and 1x10'^ M. BP, 4TB, DEt, DP, DB, NDE and DE were used in 
the final concentrations of 1x10'^ M, 1x10’® M, IxlO'^^ M, 1x10^ M, IxlQ"^^ M and 
1X10”^  M. Cisplatin had no effect on cell survival at the concentration range o f 1 x 10'  ^M 
tolxfO'"* M. At the highest concentration used (IxfO'^ M) cell survival was reduced to 
19% (Figure 3, page 36). There was a moderate dose response when cells were treated 
with 4TB and NDE. At the highest concentration of 1 xfO"  ^M, 4TB and NDE had 43% 
and 44%, respectively (Figure 3, page 36). DU-145 had similar dose response to DEt as 
to DE treatment with survival decreased at IxlO"^^ M. Cytotoxic effects o f BP, DP and 
DB on DU-145 cells were very similar with survival greatly decreased to less than 15% 
at 1X10'^^ M (Figure 3, page 36).
3.1.3 Cytotoxic effects of cisplatin and its analogs on MCF-7 cells
For MCF-7 cells, cisplatin was used in the final concentrations of 1 x 10*^  M, 1x10’ 
 ^M, 1X10’'* M and 1 x 10'  ^M. BP, 4TB, DB and DE were used in the final concentrations 
of 1x10'^ M, 1x10'^ M, 1x10'^  ^M, 1x10'^ M, 1x10^ ^  M and 1x10'^ M. Cisplatin had 
little effect on cell survival at the concentration range of 1 x 10'  ^M to 1 x M .  At the 
highest concentration used (1x10’^  M) cell survival was reduced to 12% (Figure 4, page 
37). At the highest concentration of BP (IxfO'^ M) cell survival was reduced to 15%.
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4TB appears to have stimulated growth in the concentration range of 1 x 10'  ^M to 1x10'
M and had no effect on MCF-7 survival at concentration range of 1 x 10'  ^M to 1 xIC'* M 
(Figure 4, page 37). The effects of DE at low concentrations were similar to that of 4TB; 
at concentrations of 1 x 10'^ M to 1x10'^^ M DE appears to have stimulated growth. Cell 
survival started to decrease at 1x10^^ M and there was less than 1% survival at Ixlft^ 
M. MCF-7 was most sensitive to DB with survival rate starting to decrease at 1 x IQ'^^ M 
and had less than 1% survival at 1 xlQ"^  ^M (Figure 4, page 37).
3.1.4 Cytotoxic effects of cisplatin and its analogs on MDA-MB-435 cells
For MDA-MB-435 cells, cisplatin, BP, 4TB, DEt, DP, DB, NDE and DE were 
used in the final concentrations of 1 x 10'  ^M, 1 x 10'  ^M, 1x10'^^ M, 1 x 10'  ^M, 1x10’'*^  M 
and 1x10'"  ^ M. MDA-MB-435 had a dose response to all drugs used. All the analogs 
were more effective than cisplatin and all novel analogs were more effective than BP. 
Cisplatin had little effect on cell survival at the concentration range of 1 x 10'  ^M to 1x10'^ 
M, but cell survival was reduced to 6.54 ± 1.11% at the highest concentration used (1x10' 
 ^ M) (Figure 5, page 38). BP had little effect on cell survival at the concentration range 
of 1x10'^ M to 1x10'^ M. Survival rate was significantly decreased to less than 1% at 
IxlC'*^ M. A change in survival rate of cells treated with the novel analogs were 
observed at 1x10'^^ M with 4TB having 17%, DEt having 38%, DP having 0.7%, DB 
having 14%, NDE having 63% and DE having 34% (Figure 5, page 38). All analogs had 
less than 1% survival at IxlO''* M, whereas cisplatin had 92% cell survival at the same 
concentration (Figure 5, page 38).
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3.1.5 Cytotoxic effects of cisplatin and its analogs on MDA-MB-231 cells 
For MDA-MB-231 cells, cisplatin was used in the final concentrations of 1x10’^  
M, IxlO'^M, 1x10^ M and 1x10'^ M. BP, 4TB, DB and DE were used in the final 
concentrations of 1 x 1 O’’ M, 1 x 10'  ^M, 1 x 10'^^ M, 1 x 10'  ^M, 1 x 10"^  ^M and 1 x 1 O'"* M. 
Like MDA-MB-435, MDA-MB-231 had a dose response to all drugs used. All the 
analogs were more effective than cisplatin and all novel analogs were more effective than 
BP. Cisplatin had little effect on cell survival at the concentration range of 1 x 10'  ^M to 
1x10^  ^M, but cell survival was significantly decreased to 6% at the highest concentration 
used (1X10'  ^M) (Figure 6, page 39). Similar to MDA-MB-435, BP had little effect on 
MDA-MB-231 cell survival at the concentration range of 1 x 10'  ^M to 1 x 10’^  M.
Survival rate was significantly decreased to less than 1% at 1x10'^^ M. A change in 
survival rate of cells treated with 4TB was observed at 1x10'^^ M with 30% survival. 
Survival of cells treated with DB started decreasing at 1 x 10'  ^M with 65%. The effect of 
DE was observed at IxlQ'^ M with a survival of 68% (Figure 6, page 39). BP, DB and 
DE had less than 1% survival at IxlQ"^ M, 4TB had less than 15%, whereas cisplatin had 
98% cell survival at the same concentration (Figure 6, page 39).
3.1.6 Cytotoxic effects of cisplatin and its analogs on DC4 cells 
For DC4 cells 4TB, DB and DE were used in the final concentrations of IxlQ'^ 
M, IxlQ-^ M, 1x10-55 M, 1x10'^ M, 1x10^5 M and 1x10^ M. DC4 had similar 
sensitivity to all three drugs (Figure 7, page 40). An observable decrease in survival rate 
was seen at 1 x 10'^^ M. With all three drugs there were less than 5% survival at 1 x 10'  ^M 
and less than 1% at 1x10'"*  ^M.
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3.1.7 Cytotoxic effects of cisplatin and its analogs on DB46 cells 
For DB46 cells 4TB, DB and DE were used in the final concentrations of 1x10'^ 
M, 1X1 O'® M, 1X10'^^ M, 1X10'  ^M, 1X10'  ^® M and 1X10'"^  M. DB46 had a dose response 
to the analogs comparable to that of DC4 cells. A noticeable decline in survival rate was 
seen at 1x10'® ® M. At 1x10“^  ® M cells treated with DB and DE had less than 1% 
survival, while 4TB had 10% survival (Figure 8, page 41).
3.1.8 Statistical analysis of data from clonogenic survival assays with drugs alone 
EC50 values (Table 1, page 42) were determined from the results of clonogenic 
survival assays. Student’s t-tests were used to verify significant differences among the 
EC50 values within the cell lines and between cell lines. Student’s t-test comparing 
EC50 values of A549 cells indicate statistically significant differences between DP and 
cisplatin, DB and cisplatin, and DE and cisplatin. The difference between cisplatin and 
the other analogs (BP, 4TB, DEt and NDE) were not compared as EC50 values were not 
obtained for those analogs. There are no statistical significant differences between DP 
and DB, and DP and DE. There is statistically significant difference between DB and 
DE. For DU-145, EC50 values of each of the analogs have statistically significant 
differences compared to cisplatin. EC50 values of DP and DB are statistically different 
than BP, 4TB, NDE and DE. EC50 value of DEt is statistically different than DP, DB, 
NDE and DE. For MCF-7 eells, EC50 values are statistically significant for BP and 
cisplatin, DB and cisplatin, and DE and cisplatin. There are no statistical significance 
between DB and BP, and DE and BP; however, there is a statistically significant 
difference between DB and DE. In MDA-MB-435 cells, each of the analogs is 
significantly different from cisplatin. Also, each of the analogs containing the arms at the
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4, 4' positions is statistically significant compared to BP. There are no statistical 
significant differences between each of the novel analogs except for DP and NDE. In 
MDA-MB-231 cells, there are statistically significant differences between BP and 
cisplatin, 4TB and cisplatin, DB and cisplatin, and DE and cisplatin. There are 
statistically significant differences between 4TB and BP, DB and BP, and DE and BP. 
There are also statistically significant differences between DB and 4TB, and DE and 
4TB. Finally, MDA-MB-231 also has statistically significant difference between DB and 
DE. EC50 values of 4TB, DB and DE in DC4 and DB46 cells do not show statistically 
significant differences within the eell line.
EC50 values were also compared between cell lines to determine significance. 
There are no statistical significance in the EC50 values of cisplatin between the cell lines, 
except between A549 and DU-145, A549 and MCF-7, A549 and MDA-MB-435, and 
A549 and MDA-MB-231. BP and 4TB also do not show significant differences between 
EC50 values in the eell lines. EC50 values of DEt are significantly different between 
DU-145 and MDA-MB-435 cells. EC50 values of DP are not significantly different 
between the cell lines tested, except between A549 and DU-145. EC50 value of DB for 
A549 is statistically significant when compared to each of the other cell lines. EC50 
value of DB for DU-145 is not statistically different compared to EC50 values of MDA- 
MB-435, MDA-MB-231, DC4 and DB46; however, it is statistically different compared 
to EC50 value of MCF-7. EC50 value of DB for MCF-7 is statistically significant 
compared to MDA-MB-435, MDA-MB-231, DC4 and DB46 cells. EC50 values of DB 
are not statistically significant between MDA-MB-435 and MDA-MB-231, MDA-MB- 
435 and DC4, MDA-MB-435 and DB46, MDA-MB-231 and DC4, MDA-MB-231 and
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DB46, and DC4 and DB46. EC50 values of NDE are significantly different between 
DU-145 and MDA-MB-435. Finally, EC50 value of DE for A549 is not significantly 
different from DU-145, MCF-7 and DB46, but is significantly different from MDA-MB- 
435, MDA-MB-231 and DC4. EC50 value of DE for DU-145 is statistically significant 
when compared to EC50 values of MCF-7, MDA-MB-435, MDA-MB-231, and DC4. 
There is no statistical significance between DE EC50 value of DU-145 and DB46. EC50 
value of DE for MCF-7 is statistically significant when compared to EC50 values of 
MDA-MB-435, MDA-MB-231, DC4 and DB46. DE EC50 values are statistically 
significant between MDA-MB-435 and MDA-MB-231, and MDA-MB-231 and DC4.
3.1.9 Combination treatment of A549 cells with cisplatin analogs and IR 
A549 cells were treated with IR or the combination of EC50 DB + IR, EC50 DE 
+ IR, 1x10^ M (100 pM) 4TB + IR, 1x10^ M (100 pM) cisplatin + IR and 1x10^ M 
(1000 pM) cisplatin + IR. A549 had a dose response to all treatments (Figure 9, page 
43). Treatment with the combination of 1x10^ M (100 pM) 4TB + IR had similar 
response to that of IR alone; whereas, the combination of IxlO’"^ M cisplatin + IR was 
less effective. Treatment with EC50 DB + IR, EC50 DE + IR and 1x10'^ M cisplatin + 
IR were more effective than IR alone. The combination index (Cl) was calculated and 
plotted against fraction affected (fa), except for 4TB+IR which did not have enough 
points to be plotted (Figure 10, page 44). When C K l the treatments are synergistic, 
when CI=1 the treatments are additive and when CI>1 treatments are antagonistic. As 
shown in Figure 10 (page 44), all the curves of the combination treatments are above 
CI=1 in the range of fraction affected from 0.1-0.6. The general trend o f the curves
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indicates as the fraction affected increases (percent survival decreases) Cl values 
decrease. 1 xlO'^ M cisplatin + IR had the lowest Cl values.
3.1.10 Combination treatment of DU-145 cells with cisplatin analogs and IR
DU-145 cells were treated with IR or the combination of EC50 cisplatin + IR, 
EC50 4TB + IR, EC50 DB + IR and EC50 DE + IR. DU-145 had a dose response to all 
treatments and all combination treatments were more effective than IR alone (Figure 11, 
page 45). From the Fa vs Cl graph (Figure 12 A, page 46) EC50 4TB + IR treatment had 
the highest Cl values. Cl values decreases as fraction affected increases (Figure 12 B, 
page 46). At 0.55 fraction affected the combination of DB + IR gave a Cl value of 0.99; 
at this point the concentration of DB used in combination with IR was 2.5 pM and IR 
dose was 0.68 Gy. At 0.6 fraction affected the combination of DE + IR gave a Cl of 
0.64; at this point the concentration of DE used in combination with IR was 22.2 pM and 
IR dose was 0.79 Gy.
3.1.11 Combination treatment of MCF-7 cells with cisplatin analogs and IR
MCF-7 cells were treated with IR or the combination of EC50 cisplatin + IR,
IxlO-^M 4TB + IR, EC50 DB + IR and EC50 DE + IR. MCF-7 had a dose response to 
all treatments and all combination treatments were more effective than IR alone (Figure 
13, page 47). The combinations of EC50 DB + IR and EC50 DE + IR were more 
effective than EC50 cisplatin + IR, 1x10"  ^M 4TB + IR. Not enough data was available 
to calculate Cl values for 1x10'^ M 4TB + IR. From the Fa vs Cl graph (Figure 14 A, 
page 48) EC50 cisplatin + IR treatment had the highest Cl values. Cl values decreases as 
fraction affected increases (Figure 14, A and B; page 48). Cl values for EC50 cisplatin + 
IR and EC50 DE + IR were higher than 1 for fraction affected from 0.1 to 0.8. At 0.7
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fraction affected the CI value for EC50 DB + IR is 0.89 (drug concentration used in 
combination with IR was 6.4 pM and IR dose was 0.85 Gy) and at 0.8 fraction affected 
the Cl value was 0.80 (drug concentration was 6.4 pM and IR dose was 0.98 Gy).
3.1.12 Combination treatment of MDA-MB-435 cells with cisplatin analogs and IR 
MDA-MB-435 cells were treated with IR or the combination of EC50 cisplatin +
IR, EC50 M 4TB + IR, EC50 DB + IR and EC50 DE + IR. MDA-MB-435 had a dose 
response to all treatments and all combination treatments were more effective than IR 
alone (Figure 15, page 49). The combination of EC50 DB + IR was most effective 
among the analogs. From the Fa vs Cl graph (Figure 16, page 50) EC50 cisplatin + IR 
treatment had the highest Cl values. Cl values decreases as fraetion affected increases 
(Figure 16, A and B; page 50). Cl values for EC50 cisplatin + IR, EC50 4TB + IR and 
DE + IR were higher than 1 for the range of fraction affected from 0.1 -  0.6. At 0.6 
fraction affected the Cl value for DB + IR is 0.95 (drug concentration used in 
combination with IR was 2.5 pM and IR dose was 0.77 Gy).
3.1.13 Combination treatment of MDA-MB-231 cells with cisplatin analogs and IR 
MDA-MB-231 cells were treated with IR or the combination of EC50 cisplatin +
IR, EC50 M 4TB + IR, EC50 DB + IR and 15.3 pM DE + IR. MDA-MB-231 had a dose 
response to all treatments and all combination treatments were more effective than IR 
alone (Figure 17, page 51). MDA-MB-231 had similar sensitivity to EC50 cisplatin + IR, 
EC50 M 4TB + IR and EC50 DB + IR. The combination of 15.3 pM DE + IR was most 
effective among the analogs, with survival reduced to less than 1% at 1 Gy. From the Fa 
vs Cl graph (Figure 18, page 52) EC50 DB + IR treatment had the highest Cl values. Cl 
values decreases as fraction affected increases (Figure 18, A and B; page 52). Cl values
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for EC50 cisplatin + IR and EC50 DB + IR were higher than 1 for the range of fraction 
affected from 0.1 -  0.6. At 0.6 fraction affected the Cl value for EC50 4TB + IR is 0.95 
(drug concentration used in combination with IR was 4.1 pM and IR dose was 0.99 Gy) 
and the Cl value for EC50 DE + IR is 0.90 (drug concentration used in combination with 
IR was 15.3 pM and IR dose was 0.60 Gy).
3.2 Flow Cytometry
3.2.1 Propidium Iodide Staining 
As described in Materials and Methods, propidium iodide (PI) staining was used 
to assess the cell cycle distribution of cells after 1 hour treatment with various drugs and 
fixed for analysis after 24 and 48 hours. EC50 concentrations or, in cases in which the 
EC50 concentration was unobtainable, the highest concentration (1 x lO'"* M) used in the 
elonogenic survival with drug alone of DB, DE and 4TB were used to treat A549, DU- 
145, MCF-7, MDA-MB-435 and MDA-MB-231 cell lines. EC50 concentrations or 1 x 
10'  ^M of BP, DEt, DP and NDE were only used to treat A549, DU-145 and MDA-MB- 
435 cell lines. Each experiment was done at least twice in all three cell lines tested. 
Some results were not reproducible giving very high errors.
At both 24 and 48 hours after one hour treatment with DB, DE and 4TB, A549 
cells had similar cell cycle distribution as control with the majority of the cells in the G1 
and S phases, and very little in the G2/M phases (Figure 19, A and B; page 53). There are 
significant differences with the percent of apoptosis between control and DB, and DB and 
DE treated cells for both 24 and 48 hours after treatment. There are also differences in 
the percent of cells in the G2/M phase between DB and DE and DB and 4TB at 24 hours
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after treatment. Additionally, there is a difference in the percent of cells in the S phase 
between DB and 4TB treated cells at 24 hours after treatment. At 48 hours after 
treatment, DB and 4TB has a difference in the percent of apoptosis; DE and 4TB treated 
cells has differenees in the percent of G1 and S phases. A549 cells treated with BP, DEt, 
DP and NDE had similar cell cycle distribution as the control at both 24 and 48 hours 
after treatment (Figure 19, C and D; page 53). There was an increase in apoptosis when 
cells were treated with BP, DEt, DP and NDE at 24 hours after the 1 hour treatment 
(Figure 19 C, page 53); however, there are only differences between control and DEt and 
control and DP. There are no differences in the Gl, G2/M and S phases between control 
and the treatment groups. At the 48 hours, the control had more apoptosis than BP, DEt 
and NDE treated less, but less than DP treated cells (Figure 19 D, page 53), but with 
errors taken into consideration there are no statistically significant differences. All 
treatment groups had similar Gl levels as the control, except DEt treated cells which had 
a slight decrease in Gl phase (not statistically significant with errors taken into 
consideration). There was an increase in G2/M phase and a deerease in S phase in cells 
treated with BP and DP; the difference in G2/M phase is statistically significant between 
control and both treatment groups, but not significant for S phase. DEt treated cells had a 
similar level of G2/M phase, but an increase in S phase cells compared to the control (not 
statistically significant with errors taken into consideration). NDE caused a slight 
inerease in G2/M phase, but decrease in S phase (not statistically significant with errors 
taken into consideration). When comparing the treatment groups, BP and DEt have 
differences in G2/M and S phases at the 48 hours; BP and DP have differences in Gl 
phase at 24 hours and apoptosis at 48 hours; DEt and DP have differences in apoptosis
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and G2/M phase at 48 hours; DEt and NDE have differences in G2/M phase at 24 hours, 
and apoptosis and Gl phase at 48 hours; and DP and NDE have difference in apoptosis at 
48 hours.
The results for DU-145 cells treated with 4TB, DB and DE like that of A549 were 
not reproducible, thus giving very large errors. At both 24 and 48 hours, treatment 
groups had higher percent of apoptotic cells than control; except for DE at 24 hours 
(Figure 20, A and B; page 54). Also, at both 24 and 48 hours treatment groups appears to 
have caused an increase in Gl and S phase, and the G2/M phase was similar to control. 
With the errors taken into consideration, there are no statistically significant differences 
between the treatment groups and the control. For cells treated with BP, DEt, DP and 
NDE there was also an increase in the percent of apoptosis at both 24 and 48 hours 
compared to controls (Figure 20, C and D; page 54). At 24 hours, all treatment groups 
had similar or an increase in Gl phase and a decrease in S phase compared to control. 
The percent of G2/M phase was similar or decreased compared to control in all treatment 
groups. At 48 hours, all treatment groups had a slight decrease in Gl phase and a n 
increase in G2 phase. With errors taken into consideration, there are no significant 
differences in Gl, G2/M and S phases between control and any of the treatment groups 
for both 24 and 48 hours, except BP treated cells in the Gl phase at 48 hours.
In MCF-7 cells, there was a very small increase in apoptosis when cells were 
treated with 4TB, DB and DE at both 24 and 48 hours after treatment (Figure 21, page 
55). At the 24 hours, treatment groups had a slight increase in Gl and G2/M phases and 
a decrease in S phase. However, when the error bars are taken into consideration 
treatment groups has similar cell cycle distribution as the control (Figure 21 A, page 55).
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At 48 hours, cell cycle distributions of treatment groups are similar to the control; except 
for an increase in G2/M phases was observed for cells treated with DE (Figure 21 B, page
55^
MDA-MB-435 cells treated with 4TB and DE had a similar cell cycle distribution 
at both 24 and 48 hours after 1 hour treatment (Figure 22, A and B; page 56). At 24 
hours, the majority of the cells were in the S phase and approximately equal amount of 
cells in Gl and G2/M phases. The percent of cells in the S phase for both 4TB and DE 
were higher than control, whereas the percent of Gl and G2/M phases were slightly less. 
Cells treated with DB had an increase in apoptosis and G2/M phases, and a decrease in 
Gl and S phases. Large errors indicate that the results are not statistically significant. At 
48 hours, cells treated with 4TB, DB and DE had about equal amount of cells distributed 
between Gl and S phases. The percent of cells in Gl phase was higher than control and 
the percent of cells in the S phase was higher than control. DB treated cells also had an 
increase in apoptosis compared to control (Figure 22 B, page 56). The percent o f cells in 
the G2/M phases was similar between control and the treatment groups. MDA-MB-435 
cells were also treated with EC50 concentration of BP, DEt, DP and NDE for PI analysis 
with flow cytometry. At 24 hours after 1 hour treatment, treated cells had comparable 
level of apoptotic cells as control, except DP and NDE treated cells which had an 
increase in apoptosis (Figure 22 C, page 56). The level of Gl phase was decreased in 
cells treated with BP, DP and NDE, but increased in cells treated with DEt. The percent 
of G2/M phase was similar to control for cells treated with DEt and DP, but higher than 
control for BP and NDE treated cells. DP treated cells had a higher level of S phase than 
control; where BP, DEt and NDE treated cells had a decrease in S phase. At 48 hours,
30
R ep ro d u ced  with p erm issio n  o f  th e  copyrigh t ow n er. Further reproduction  prohibited w ithout p erm ission .
there was a similar percent of apoptosis in cells treated with BP, DEt and DP and 
significantly higher in NDE treated cells (Figure 22 D, page 56). BP, DEt and NDE 
treated cells had similar or lower percent of Gl phase than control while DP treated cells 
had higher Gl phase. BP and NDE treated cells had an increase in G2/M phases and DEt 
and DP had similar or a decrease in G2/M phases compared to control. All treatment 
groups had similar or lower S phase cells compared to control (Figure 22 D, page 56). 
With errors taken into consideration, these results are not significant.
MDA-MB-231 cells were treated with EC50 concentrations of 4TB, DB and DE 
for PI analysis with flow cytometry 24 and 48 hours after 1 hour treatment. At 24 hours, 
cell cycle distribution of treatment groups was similar to control (Figure 23 A, page 57), 
The majority of the cells were in the S phase. Cells treated with DE and 4TB had an 
increase in apoptosis and a decrease in Gl phase. DB treated cells also had a decrease in 
Gl phase, but the level of apoptosis was similar to control. DB and 4TB treatment 
caused an increased in G2/M phase, while DE treatments has similar level as control. 
4TB and DB treatment caused a slight decrease in S phase, and DE treatment caused an 
increase. At 48 hours, cells were more evenly distributed within the cell cycle with the 
Gl and S phase having slightly higher level of cells than G2/M phases (Figure 23 B, page 
57). An increase in apoptosis was observed in treated cells. Cells treated with DE had 
the most noticeable differences; there was an increase in apoptotic cells and an increase 
in G2/M and S phases. DE treatment also caused a decrease in Gl phase. DB and 4TB 
treated cells had a similar cell cycle distribution as control. Large errors indicate that 
there is no statistically significant difference between treatment groups and control at 
both 24 and 48 hours.
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3.2.2 Annexin V Staining 
As described in Materials and Methods, MDA-MB-435 cells were treated for 1 
hour with EC50 concentrations of cisplatin and each of the analogs and analyzed by flow 
cytometry with Annexin V staining at 24 and 48 hours after treatment. Results for 
Annexin V staining are presented in Table 2 (page 58). At 24 hours, all treatment groups 
had a higher percent of apoptotie cells than control (8% apoptotic). DEt, DP, DB and 
NDE had higher percent of necrotic cells than control BP (12% apoptotic and 2% 
necrotic cells) and 4TB (20% apoptotic and 1% necrotic) treatment groups had similar or 
lower percent of apoptotic and necrotic cells than cisplatin (20% apoptotic and 0.8% 
necrotic). DEt (23% apoptotic and 16% necrotic cells) and DE (13% apoptotic and 5% 
necrotic) treated cells had similar or lower percent of apoptotic cells and higher percent 
of necrotic cells than cisplatin. DP (54% apoptotic and 23% necrotic cells), DB (56% 
apoptotic and 24% necrotic cells) and NDE (35% apoptotic and 10% necrotic cells) had a 
higher percent of apoptotic and necrotic cells than control, cisplatin, BP, 4TB and DE 
treated groups. NDE had a higher percent of apoptosis than DEt, but a lower percent of 
necrosis. DP and DB had higher percent apoptotic and necrotic cells than DEt and NDE. 
DB had similar percent of apoptotic and necrotic cells as DP. At 48 hours, cisplatin (9% 
apoptotic and 2% necrotic) and 4TB (9% apoptotic and 2% necrotic) treated cells had 
similar percent of apoptotic and necrotic cells than control (8% apoptotic and 2% necrotic 
cells); all other treatment groups had higher percent of apoptotic and necrotic cells than 
control. Cells treated with BP (30% apoptotic and 9% necrotic cells), DP (53% apoptotic 
and 24% necrotic cells), DB (40% apoptotic and 23% necrotic cells), NDE (28% 
apoptotic and 17% necrotic cells) and DE (11% apoptotic and 5 necrotic cells) had a
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higher percent of apoptotic and necrotic cells than cisplatin (9% apoptotic and 2% 
necrotic cells). Cells treated with 4TB had similar percent of apoptotie and necrotic cells 
as cisplatin. DEt (10% apoptotic and 8 percent necrotic) had similar percent of apoptotic 
cells as cisplatin, but higher percent of neerotic cells. DP, DB and NDE had a higher 
percent of apoptotic and necrotic cells than BP. DP and DB had a higher percent of 
apoptotic and necrotic cells than DEt. DP had a higher percent of apoptotic cells than DB 
and both had similar percent of necrotic cells. NDE had a higher percent of apoptotic and 
necrotic cells than DE.
3.3 DNA Laddering
MDA-MB-435 cells were set up and treated with EC50 concentrations of cisplatin 
and the analogs. At 24 hours after treatment, DNA was extracted and separated by 
agarose gel electrophoresis as described in Materials and Methods. DNA laddering or 
smearing indicates cells undergoing apoptosis. Presented in Figure 24 A (page 59) is a 
picture of the gel for one individual trial. Samples for DP and DEt were lost and thus are 
not shown on the gel. A light smear was observed for control, possibly due to being too 
confluent. Smearing of DNA was also observed for BP, NDE and DB treatment groups. 
The smearing of DNA in the DB lane was very apparent. Presented in Figure 24 B (page 
59) is the picture of the gel for a repeated trial. Smearing of DNA was observed for DP, 
DB and NDE treated cells as was seen in Figure 24 A. Similar to Figure 24 A, no 
smearing of DNA was observed for cisplatin treated cells. A DNA smear was not 
observed for positive control cells, most likely because the samples were old. Unlike 
Figure 24 A, no smearing of DNA was observed for BP treated cells, could be caused by
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low amount of cells. Finally, DNA smearing was also not seen for DEt treated cells. 
These results are consistent with data for flow cytometry.
3.4 Fluorescent Microscopy 
MCF-7 cells were treated with BP, 4TB, and DB for 1 hour and microscope 
images were taken as described in Materials and Methods. Representative images of 
bright field, Hoechst staining and PI staining for control and treated cells are presented in 
Figure 25 (page 60). Data obtained from the images are presented in Table 3 (page 61). 
All treatment groups had higher percent of apoptosis and necrosis than control. There 
were more apoptosis than necrosis. The percent of apoptosis and necrosis were higher in 
DB treated cells than in 4TB treated cells. The percent of apoptosis was higher for DB 
treated cells than BP treated cells; however, the percent of necrosis was less in DB treated 
cells. Student’s t-test indicates a statistically significant difference between BP treated 
cells and control for apotosis, but not for 4TB and DB treated cells. There are no 
statistically significant differences between the treatment groups. For necrosis, there are 
statistically significant differences between all three treatment groups and the control. 
There is also a statistically significant difference between DB and 4TB treated cells. 
These results confirmed the data obtained fi'om flow cytometry and DNA laddering; the 
drugs tend to induce more apoptosis than necrosis, although, the levels are different from 
one cell line to another.
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Figure 2. Clonogenic survival curves of A549 cells. Cells were treated for 1 h with 
varying concentrations of cisplatin or its analogs. Cell survival was assessed by 
normalizing the number of colonies (50 or more cells) formed for treated cells with 
controls. Data points are the average of two individual clonogenic survival assays each 
done in triplicate plates or more, except the data point for DE at 1.0 x 10"^  was from a 
single trial. Data points for DEt are the average of three individual clonogenic survival 
assays. All averaged data points have error bars representing standard deviation.
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Figure 3. Clonogenic survival curves of DU-145 cells. Cells were treated for 1 h with 
varying concentrations of cisplatin or its analogs. Cell survival was assessed by 
normalizing the number of colonies (50 or more cells) formed for treated cells with 
controls. Data points are the average of two individual clonogenic survival assays each 
done in triplicate plates or more, except the data point for Dibutyl at 1.0 x lO''^  M was 
from a single trial. Data points for NDE are the average of three individual clonogenic 
survival assays. All average data points have error bars representing standard deviation.
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Figure 4. Clonogenic survival curves of MCF-7 cells. Cells were treated for 1 h with 
varying concentrations of cisplatin or its analogs. Cell survival was assessed by 
normalizing the number of colonies (50 or more cells) formed for treated cells with 
controls. Data points for cisplatin, BP, and Dibutyl are the average of two individual 
clonogenic survival assays each done in triplicate plates or more. Data points for 4TB 
and Diether are the average of three individual clonogenic survival assays each done in 
triplicate plates or more. Data points for 4TB at 1.0 x 10"^  ^ and 1.0 x 10"^  M are from 
one experimental trial. Data point for DE at 1.0 x 10"^  ^M is from one experimental trial. 
All averaged data points have error bars representing standard deviation.
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Figure 5. Clonogenic survival curves of MDA-MB-435 eells. Cells were treated for 1 h 
with varying concentrations of cisplatin or its analogs. Cell survival was assessed by 
normalizing the number of colonies (50 or more cells) formed for treated eells with 
controls. Data points for cisplatin are the average of 8 individual elonogenic survival 
assays each done in triplicate plates. Data points for DP and NDE are the average of 
three individual clonogenic survival assays each done in triplicate plates or more. Data 
points for the other analogs are the average of two individual clonogenic survival assays 
each done in triplicate plates or more. All average data points have error bars 
representing standard deviation.
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Figure 6. Clonogenic survival curves of MDA-MB-231 cells. Cells were treated for 1 h 
with varying concentrations of cisplatin or its analogs. Cell survival was assessed by 
normalizing the number of colonies (50 or more cells) formed for treated cells with 
controls. Data points for cisplatin are the average of 5 individual clonogenic survival 
assays each done in triplicate plates. Data points for the analogs are the average of two 
individual clonogenic survival assays each done in triplicate plates or more. The line for 
DE (dashed line) is a nonlinear regression curve. All average data points have error bars 
representing standard deviation.
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Figure 7. Clonogenic survival curves of DC4 cells. Cells were treated for 1 h with 
varying concentrations of cisplatin or its analogs. Cell survival was assessed by
normalizing the number of colonies (50 or more cells) formed for treated cells with 
controls. Data points for Diether and Dibutyl are the average of two individual 
clonogenic survival assays each done in triplicate plates or more. Data points for 4TB are 
the average of three individual clonogenic survival assays each done in triplicate plates or 
more. All averaged data points have error bars representing standard deviation.
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Figure 8. Clonogenic survival curves of DB46 cells. Cells were treated for 1 h with 
varying concentrations of cisplatin or its analogs. Cell survival was assessed by 
normalizing the number of colonies (50 or more cells) formed for treated cells with 
controls. Data points are the average of two individual clonogenic survival assays each 
done in triplicate plates or more. All averaged data points have error bars representing 
standard deviation.
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Lung Prostate Breast
A549 DU-145 MCF-7 MDA-MB-435
MDA-
MB-231 DC4 DB46
CDDP
(pM)
900 ± 
100
500 ± 
200 310±20 310±60 330 ±40
BP
(pM) >100 50 ± 20* 40 ± 30* 20 ± 1*
20.9 ± 
0.1*
4TB
(pM) >100 70 ± 40* >100 2± I*
4.1 ± 
0.9* 3± 1 3.8 ±0.9
DEt
(pM) >100
19.0 ± 
0.2* 4± 1*
DP
(pM) 20 ± 8*
2.7 ± 
0.1*
1.8±
0.8*
DB
(pM)
8.5 ± 
0.6*
2.5 ± 
0.3*
6.4 ± 
0.7*
2.5 ± 
0.3*
1.4 ± 
0.9* 1.9 ±0.4 1.5 ±0.9
NDE
(pM) >100 26 ±3* 6±3*
DE
(pM) 25 ±5* 22 ±2* 32 ±3* 3± 1* 7± 1* 1.9 ±0 10±6
Statistical y significant compared to cisplatin within cell line wit]1 p<0.05.
Table 1. EC50 values determined from clonogenic survival assays
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Figure 9. Clonogenic survival curves of A549 treated with ionizing radiation (IR) alone 
or in combination with cisplatin or its analogs. Cells were treated for 1 h with cisplatin or 
its analogs (EC 50 concentration or the highest concentration used in clonogenic survival 
with drug alone) and then irradiated with IR at a rate of 1 Gy/min. Cell survival was 
assessed by normalizing the number of colonies (50 or more cells) formed for treated 
cells with controls. Data points for IR and 1.0 x 10'  ^ M CDDP +IR are the average of 
three individual clonogenic survival assays, each done in triplicate plates or more. All 
other data points are the average of two individual clonogenic survival assays each done 
in triplicate plates or more. All averaged data points have error bars representing 
standard deviation.
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Figure 10. A549 combination index curve. CI values were calculated with data taken 
from the average clonogenic survival curves. Did not have enough data to construct a 
curve for 4TB + IR.
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Figure 11. Clonogenic survival curves of DU-145 treated with ionizing radiation (IR) 
alone or in combination with cisplatin or its analogs. Cells were treated for 1 h with 
cisplatin or its analogs (EC50 concentration) and then irradiated with IR at a rate of 1 
Gy/min. Cell survival was assessed by normalizing the number of colonies (50 or more 
cells) formed for treated cells with controls. Data points for IR are the average of four 
individual trials and data points for CDDP +IR are the average of three individual 
clonogenic survival assays, each done in triplicate plates or more. All other data points 
are the average of two individual clonogenic survival assays each done in triplicate plates 
or more. All averaged data points have error bars representing standard deviation.
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Figure 12. DU-145 combination index curve. CI values were calculated with data taken 
from the average clonogenic survival curves. (A) Cl curves of all combination 
treatments. (B) A more magnified graph of Cl curves with the curve for 4TB + IR 
removed.
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Figure 13. Clonogenic survival curves of MCF-7 cells treated with ionizing radiation 
(IR) alone or in combination with cisplatin or its analogs. Cells were treated for 1 h with 
cisplatin or its analogs (EC50 concentration or the highest concentration used in 
clonogenic survival with drug alone) and then irradiated with IR at a rate of 1 Gy/min. 
Cell survival was assessed by normalizing the number of colonies (50 or more cells) 
formed for treated cells with controls. Data points for IR, DB+IR and DE+IR are the 
average of three individual trials each done in triplicate plates or more. Data points for 
CDDP+IR and 4TB+IR are the average of two individual clonogenic survival assays each 
done in triplicate plates or more. All averaged data points have error bars representing 
standard deviation.
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Figure 14. MCF-7 combination index curve. Cl values were calculated with data taken 
from the average clonogenic survival curves. Did not have enough data to construct a 
curve for 4TB + IR. (A) Cl curves of cisplatin, DB and DE in combination with IR. (B) 
A more magnified graph of Cl curves with the curve for CDDP + IR removed.
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Figure 15. Clonogenic survival curves of MDA-MB-435 cells treated with ionizing 
radiation (IR) alone or in combination with cisplatin or its analogs. Cells were treated for 
1 h with cisplatin or its analogs (EC50 concentration) and then irradiated with IR at a rate 
of 1 Gy/min. Cell survival was assessed by normalizing the number of colonies (50 or 
more cells) formed for treated cells with controls. Data points for IR and DE+IR are the 
average of three individual trials each done in triplicate plates or more. Data points for 
all other combination treatments are the average of two individual clonogenic survival 
assays each done in triplicate plates or more. Data point for cisplatin + IR at 6 Gy is from 
a single experiment. All averaged data points have error bars representing standard 
deviation.
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Figure 16. MDA-MB-435 combination index curve. Cl values were calculated with 
data taken from the average clonogenic survival curves. (A) Cl curves of all combination 
treatments. (B) A more magnified graph of Cl curves with the curve with Cl values at 
0.1 fraction affected removed.
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Figure 17. Clonogenic survival curves of MDA-MB-231 cells treated with ionizing 
radiation (IR) alone or in combination with cisplatin or its analogs. Cells were treated for 
1 h with cisplatin or its analogs (EC50 concentration) and then irradiated with IR at a rate 
of 1 Gy/min. Cell survival was assessed by normalizing the number of colonies (50 or 
more cells) formed for treated cells with controls. Data points for IR are the average of 
five individual clonogenic survival assays. Data points for CDDP+IR.and DE+IR are the 
average of three individual trials each done in triplicate plates or more. Data points for 
4TB+IR and DB+IR are the average of two individual clonogenic survival assays each 
done in triplicate plates or more. All averaged data points have error bars representing 
standard deviation.
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Figure 18. MDA-MB-231 combination index curve. Cl values were calculated with 
data taken from the average clonogenic survival curves. (A) Cl curves o f all combination 
treatments. (B) A more magnified graph of Cl curves with the curve with Cl values at 
0.1 and 0.2 fraction affected removed.
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Figure 19. Flow cytometry with PI staining of A549 cells after Ih treatment with EC50 
concentrations of cisplatin analogs. Samples were analyzed 24h and 48h after treatment. 
Results presented are the average of two individual trials with error bars representing 
standard deviation.
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Figure 20. Flow cytometry with PI staining of DU-145 cells after Ih treatment with 
EC50 concentrations of cisplatin analogs. Samples were analyzed 24h and 48h after 
treatment. Results are the average of two individual trials with error bars representing 
standard deviation.
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Figure 21. Flow cytometry with PI staining of MCF-7 cells after Ih treatment with EC50 
concentrations of cisplatin analogs. Samples were analyzed 24h and 48h after treatment. 
Results are the average of two individual trials with error bars representing standard 
deviation.
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Figure 22. Flow cytometry with PI staining of MDA-MB-435 cells after Ih treatment 
with EC50 concentrations of cisplatin analogs. Samples were analyzed (A and C) 24h 
and (B and D) 48h after treatment. Results are the average of two individual trials with 
error bars representing standard deviation.
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Figure 23. Flow cytometry with PI staining of MDA-MB-231 cells after Ih treatment 
with EC50 concentrations of cisplatin analogs. Samples were analyzed 24h and 48h after 
treatment. Results are the average of two individual trials with error bars representing 
standard deviation.
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24 hours 48 hours
Apoptotic (%) Necrotic (%) Apoptotic (%) Necrotic (%)
Control 8 ± 3 7 ± 9 8 ± 2 2 ± 1
CDDP 20 ± 10 0.8 ±0.3 9 ±  1 1.6 ± 0 .7
BP 1 2 ± 5 2 ± 2 30 ± 6 9 ± 9
4TB 20 ± 20 1 ± 1 9 ± 3 2 ±  1
DEt 23 ± 4 15.94 ±0.08 10± 1 8 ± 7
DP 54 ± 4 23 ± 4 53 ±1 24 ± 7
DB 56 ± 3 24 ± 3 40 ±20 2 3 ± 2
NDE 3 5 ± 4 10 ± 1 28 ± 7 1 7 ± 9
DE 13 ± 9 5 ± 7 11 ± 3 5 ± 5
Table 2. Flow cytometry with Annexin V staining of MDA-MB-435 cells. Cells were 
treated for 1 hour with EC50 concentration of cisplatin or its analogs. Samples were 
analyzed after 24 and 48 hours. Values are the average of two individual experiments.
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Figure 24. DNA laddering of MDA-MB-435. Cells were treated for 1 hour with EC50 
concentrations of cisplatin and its analogs. 24 hours after treatment, total DNA was 
extracted and separated by agarose gel electrophoresis. Laddering of DNA is a hallmark 
for apoptosis. (A and B) Two individual trials.
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Figure 25. MCF-7 microscope images. Cells were treated with values from EC50 table 
for 1 hour and images were taken 48 hours after treatments. Cells were stained with 
Hoechst and PI. (A-C) Control, (D-F) BP, (G-I) 4TB and (J-L) DB. (A, D, G, J) bright 
field, (B, E, H, K) Hoechst and (C, F, I, L) PI. Brightly glowing cells were eounted as 
positive for Hoechst and PI. Arrows point to examples of positive eells.
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% Apoptosis % Necrosis
control 2 ±  1 0.3 ±0.3
BP 8 ± 4 7 ± 8
4TB 4 ±  1 1.0 ±0.7
DB 10±4 3 ± 3
Table 3. MCF-7 fluorescent microscope data. Cells from bright field, Hoechst and PI 
images were counted and the percent of apoptosis and necrosis were calculated based on 
the number of positive cells for Hoechst and PI as a percent of the total number of cells in 
the bright field images. Values represent the average and standard deviation of two 
individual experiments.
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CHAPTER 4 
CONCLUSIONS
This study characterized the ability of seven cisplatin analogs (five of whieh are 
novel) to kill lung, prostate and breast cancer cell lines. All of the novel compounds 
showed some ability to kill cancer cells, although their cytotoxicity varied from cell line 
to cell line. All the cisplatin analogs appeared to kill the cancer cells predominately by 
apoptosis although some necrosis was observed. The most lethal analog, DB, was 
anywhere from 47 to 242 times more lethal than cisplatin in the three cancer cell types 
investigated. The cisplatin analogs did not typically cause a block in the cell cycle. 
Several of the cisplatin analogs had slightly synergistic interaction with ionizing radiation 
to kill prostate (DE) and breast (DB, 4TB, DE) cancer cell lines.
The literature contains many descriptions of novel cisplatin analogs; over several 
thousand have been published (Weiss and Christian, 1993). Two analogs that are similar 
in structure to those reported here have been recently described (Elwell et al., 2006). 
Both analogs contained a bipyridine ring system to which substitutents had been added to 
the 4,4’ positions. These analogs were 14 to 125 times more lethal than cisplatin in 
breast, prostate and lung cancer cell lines and appeared to kill eells via apoptosis (Elwell 
et al., 2006). These findings are consistent with the observations reported in this study.
The cisplatin analogs used in this study allow for some interesting observations on 
the structme/function activity of these compounds. The addition of the bipyridine ring
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system to cisplatin resulted in a 10-fold increase in lethality in prostate and breast cancer 
cell lines. The addition of substitutents at the 4,4’ positions on the bipyridine ring system 
could result in up to another 10 to 20 fold increase in lethality. The results with the DB 
analog described here indicate that the addition of fluorine atoms at the end of the 4,4’ 
substitutents does not result in any increased lethality (Elwell et al., 2006). The length of 
the 4,4’ substitutent was compared in a homologous series (BP, DEt, DP, DB) in both a 
prostate (DU-145) and breast (MDA-MB-435) cancer cell line. Substitutent length had 
no effect in the breast cancer cell line; however, a large effect was observed in the 
prostate cancer cell with three or four carbons providing the greatest cell kill. The 
position of a methoxy functional group was not important in breast (MDA-MB-435) or 
prostate (DU-145) cancer cell lines, but did play a role in lung (A549) cancer cells with a 
longer chain length being more lethal. The shape of the 4,4’ substitutent appears to be 
important. In a comparison between DB and 4TB the straight chain was usually more 
lethal than the branched chain; however, this result was cell line specific.
The novel cisplatin analogs produced several results that were similar to cisplatin. 
The lack of any consistent effect on the cell cycle distribution for the novel cisplatin 
analogs is not surprising since cisplatin fails to yield any reproducible cell cycle effects 
(Wang and Lippard, 2005). Cisplatin is known to act synergistically with ionizing 
radiation (Stewart et al., 1994; Lawrence et al., 2003; Fehlauer et al., 2005; Wilson et al., 
2006; Rave-Frank et al., 2007) and several of the novel analogs also displayed slightly 
synergistic interactions with ionizing radiation.
The results presented here describe the function of five novel cisplatin analogs 
that are all more lethal than cisplatin. Further studies will be needed to determine if they
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can provide effective tumor killing in patients while being used at lower doses than 
cisplatin to avoid nephrotoxicity.
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APPENDIX I
CLONOGENIC SURVIVAL DATA 
The following figures illustrate two representative survival curves of each cell lines after 
treatment with 1 hour cisplatin or its analogs.
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MDA-MB-231 Clonogenic Survivals
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MDA-MB-231 Clonogenic Survival with DE
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A represents the original average survival curve 
B represents the average curve with two extra points added 
C represents the nonlinear regression curve (best fit)
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A549 Clonogenic Survivais with Combination Treatments
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MDA-MB-231 Clonogenic Survival with Combination Treatments
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APPENDIX II
COMBINATION INDEX (Cl) DATA
A549 with 100 \M  CDDP + IR
% survival Fa Drug (gM) IR(Gy) Drug combo (gM) IR combo (Gy) Cl
90 0.1 164 0.9 100 1.3 2.1
80 0.2 270 2.4 100 3.0 1.6
70 0.3 435 3.8 100 4.3 1.4
60 0.4 699 4.9 100 5.5 1.3
A549 with 1000 gM CDDP + IR
% survival Fa Drug (gM) IR(Gy) Drug combo (gM) IR combo (Gy) Cl
90 0.1 164 0.9 1000 0.2 6.4
80 0.2 270 2.4 1000 0.4 3.9
70 0.3 435 3.8 1000 0.6 2.5
60 0.4 699 4.9 1000 0.8 1.6
50 0.5 985 6.0 1000 3.5 1.6
A549 with 4TB + IR
% survival Fa Drug (gM) IR(Gy) Drug combo (gM) IR combo (Gy) Cl
90 O.I 3.9 0.9 100 0.7 26
80 0.2 50.1 2.4 100 2.0 2.8
A549 with DB + IR
% survival Fa Drug (gM) IR(Gy) Drug combo (gM) IR combo (Gy) Cl
90 0.1 0.7 0.9 8.5 0.2 13
80 0.2 2.3 2.4 8.5 0.5 3.9
70 0.3 5.2 3.8 8.5 0.7 1.8
60 0.4 6.8 4.9 8.5 0.9 1.4
50 0.5 8.8 6.0 8.5 1.9 1.3
A549 with DE + IR
% survival Fa Drug (gM) IR(Gy) Drug combo (gM) IR combo (Gy) Cl
90 0.1 4.9 0.9 24.6 0.5 5.5
80 0.2 13.5 2.4 24.6 0.9 2.2
70 0.3 16.9 3.8 24.6 1.8 1.9
60 0.4 20.2 4.9 24.6 2.9 1.8
50 0.5 24.5 6.0 24.6 4.3 1.7
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DU-145 with CDDP + IR
% survival Fa Drug (gM) IR(Gy) Drug combo (gM) IR combo (Gy) Cl
90 0.1 161 1.9 490 0.2 3.2
80 0.2 206 2.6 490 0.5 2.6
70 0.3 266 3.6 490 0.7 2.0
60 0.4 349 4.8 490 0.9 1.6
50 0.5 451 6.3 490 3.3 1.6
40 0.6 514 7.0 490 3.7 1.5
DU-145 with 4TB + IR
% survival Fa Drug (gM) IR(Gy) Drug combo (gM) IR combo (Gy) Cl
90 0.1 4.5 1.9 73.7 0.1 17
80 0.2 7.1 2.6 73.7 0.2 10
70 0.3 2.7 3.6 73.7 0.3 28
60 0.4 6.3 4.8 73.7 0.4 12
50 0.5 8.3 6.3 73.7 0.6 9.0
40 0.6 9.6 7.0 73.7 0.6 7.8
DU-145 with DB + IR
% survival Fa Drug (gM) IR(Gy) Drug combo (gM) IR combo (Gy) Cl
90 0.1 1.2 1.9 2.5 0.1 2.1
80 0.2 1.5 2.6 2.5 0.2 1.8
70 0.3 1.8 3.6 2.5 0.4 1.5
60 0.4 2.1 4.8 2.5 0.5 1.3
50 0.5 2.6 6.3 2.5 0.6 1.1
45 0.55 2.8 7.0 2.5 0.7 0.99
DU-145 with DE + IR
% survival Fa Drug (gM) IR(Gy) Drug combo (gM) IR combo (Gy) Cl
90 0.1 11.8 1.9 22.2 0.1 2.0
80 0.2 13.8 2.6 22.2 0.3 1.7
70 0.3 16.3 3.6 22.2 0.4 1.5
60 0.4 19.1 4.8 22.2 0.6 1.3
50 0 .5 22.5 6.3 22.2 0.7 1.1
40 0.6 42.3 7.0 22.2 0.8 0.64
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MCF-7 with CDDP + IR
% survival Fa Drug (gM) IR(Gy) Drug combo (gM) IR combo (Gy) Cl
80 0.2 0.92 1.5 305 0.74 332
70 0.3 17 2.3 305 1.3 19
60 0.4 23 3.1 305 2.3 14
50 0.5 31 3.9 305 3.4 11
40 0.6 42 4.7 305 4.4 8.2
30 0.7 58 6.2 305 5.6 6.2
20 0.8 78 7.0 305 6.8 4.9
MCF-7 with DB + IR
% survival Fa Drug (gM) IR(Gy) Drug combo (gM) IR combo (Gy) Cl
90 0.1 1.7 0.70 6.4 0.11 4.0
80 0.2 2.7 1.5 6.4 0.24 2.5
70 0.3 4.7 2.3 6.4 0.36 1.5
60 0.4 5.6 3.1 6.4 0.49 1.3
50 0.5 6.4 3.9 6.4 0.61 1.2
40 0.6 7.4 4.7 6.4 0.73 1.0
30 0.7 8.5 6.2 6.4 0.85 0.89
20 0.8 9.7 7.0 6.4 1.0 0.80
MCF-7 with DE + IR
% survival Fa Drug (gM) IR(Gy) Drug combo (gM) IR combo (Gy) Cl
90 0.1 14 0.70 33.2 0.11 2.5
80 0.2 16 1.5 33.2 0.22 2.2
70 0.3 19 2.3 33.2 0.33 1.9
60 0.4 22 3.1 33.2 0.43 1.6
50 0.5 26 3.9 33.2 1.1 1.6
40 0.6 31 4.7 33.2 3.5 1.8
30 0.7 36 6.2 33.2 5.0 1.7
20 0.8 42 7.0 33.2 7.0 1.8
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MDA-MB-435 with CDDP + IR
% survival Fa Drug (gM) IR(Gy) Drug combo (gM) IR combo (Gy) Cl
90 0.1 106 1.8 328 0.68 3.5
80 0.2 140 2.9 328 1.4 2.8
70 0.3 182 3.6 328 2.3 2.4
60 0.4 238 4.2 328 3.2 2.1
50 0.5 312 4.8 328 4.3 1.9
40 0.6 406 6.2 328 5.4 1.7
MDA-MB-435 with 4TB + IR
% survival Fa Drug (gM) IR(Gy) Drug combo (gM) IR combo (Gy) Cl
90 0.1 0.14 1.8 2.4 0.42 17
80 0.2 1.1 2.9 2.4 0.82 2.5
70 0.3 1.4 3.6 2.4 1.5 2.2
60 0.4 1.7 4.2 2.4 2.4 2.0
50 0.5 2.2 4.8 2.4 3.5 1.8
40 0.6 2.8 6.2 2.4 4.7 1.6
MDA-MB-435 with DB + IR
% survival Fa Drug (gM) IR(Gy) Drug combo (gM) IR combo (Gy) Cl
90 0.1 1,2 1.8 2.5 0.12 2.2
80 0.2 1.4 2.9 2.5 0.25 1.9
70 0.3 1.7 3.6 2.5 0.38 1.6
60 0.4 2.1 4.2 2.5 0.52 1.3
50 0.5 2.5 4.8 2.5 0.64 1.1
40 0.6 3.0 6.2 2.5 0.77 0.95
MDA-MB-435 with DE + IR
% survival Fa Drug (gM) IR(Gy) Drug combo (gM) IR combo (Gy) Cl
90 0.1 1.2 1.8 3.3 0.25 2.9
80 0.2 1.4 2.9 3.3 0.51 2.5
70 0.3 1.9 3.6 3.3 0.76 1.9
60 0.4 2.5 4.2 3.3 1.0 1.6
50 0.5 3.3 4.8 3.3 2.2 1.5
40 0.6 4.2 6.2 3.3 3.5 1.4
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MDA-MB-231 with CDDP + IR
% survival Fa Drug (gM) IR(Gy) Drug combo (gM) IR combo (Gy) Cl
90 0.1 122 0.60 324 0.18 3.0
80 0.2 156 1.9 324 0.37 2.3
70 0.3 201 3.5 324 0.55 1.8
60 0.4 258 4.5 324 0.74 1.4
50 0.5 332 5.3 324 0.92 1.1
40 0.6 429 6.0 324 2.0 1.1
MDA-MB-231 with 4TB + IR
% survival Fa Drug (gM) IR(Gy) Drug combo (gM) IR combo (Gy) Cl
90 0.1 1.3 0.60 4.1 0.16 3.3
80 0.2 1.8 1.9 4.1 0.32 2.5
70 0.3 2.3 3.5 4.1 0.49 1.9
60 0.4 3.1 4.5 4.1 0.65 1.5
50 0.5 4.0 5.3 4.1 0.82 1.2
40 0.6 5.2 6.0 4.1 0.99 0.95
MDA-MB-231 with DB + IR
% survival Fa Drug (gM) IR(Gy) Drug combo (gM) IR combo (Gy) Cl
90 0.1 0.12 0.60 1.4 0.26 12
80 0.2 0.28 1.9 1.4 0.53 5.3
70 0.3 0.65 3.5 1.4 0.80 2.4
60 0.4 1.2 4.5 1.4 1.3 1.5
50 0.5 1.5 5.3 1.4 2.4 1.4
40 0.6 1.9 6.0 1.4 3.6 1.3
MDA-MB-231 with DE + IR
% survival Fa Drug (gM) IR(Gy) Drug combo (gM) IR combo (Gy) Cl
90 0.1 5.7 0.60 15.3 0.11 2.9
80 0.2 7.3 1.9 15.3 0.20 2.2
70 0.3 9.4 3.5 15.3 0.30 1.7
60 0.4 12.0 4.5 15.3 0.40 1.4
50 0.5 15.3 5.3 15.3 0.50 1.1
40 0.6 19.2 6.0 15.3 0.60 0.90
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APPENDIX III
FLOW CYTOMETRY AND MICROSCOPE DATA
A549
24h Apoptotic (%) Gl^O G2/M (%) S(%)
Trial 1
control 0.6 54.68 0 45.32
DB 14.51 60.33 5.95 33.71
DE 0.79 57.49 0.2 42.3
4TB 1.73 52.91 0.19 46.9
Trial 2 control 0.81 58.46 4.61 36.93
4TB 19.78 58.68 0 41.32
Trial 3
control 1.16 64.47 3.79 31.73
DB 15.36 62.81 5.71 31.48
DE 1.3 67.04 0 32.96
Average ± SD
control 0.9 + 0.3 59 + 5 3 + 2 38 + 7
DB 14.9 + 0.6 62 + 2 5.8 + 0.2 33 + 7
DE 1.1 +0.4 62 + 7 0.1+ 0.1 38 + 7
4TB 10+10 56 + 4 0.1 +0.1 44 + 4
A549
48h Apoptotic (%) 01 (%) G2/M (%) S (% )
Trial 1
control 1.73 52.91 0.19 46.9
DB 10.34 53.58 0.2 46.22
DE 1.22 68.87 4.74 2 6 J 9
4TB 1.26 56.76 0 43.24
Trial 2
control 0.42 71.19 5.63 23.18
8DB 20.31 64.59 0 35.41
4TB 3.8 55.8 0 44.2
Trial 3
control 0.31 76.13 0.77 23.1
DB 13.97 61.7 3.28 35.02
DE 1.3 67.04 0 3 2 4 6
Average ± SD
control 0.8+ 0.8 70+ 10 2 + 3 30+10
DB 15 + 5 60 + 5 1 + 2 39 + 6
DE 1.26 + 0.06 68+1 2 ± 3 30 + 5
4TB 3 + 2 56.3+0.7 0 43.7 + 0.7
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A549
24h Apoptotic (%) G1 (%) G2/M (%) S (% )
Trial 1
control 1.17 46.39 16.9 36.72
BP 4.94 55.73 11.53 32.74
DEt 11.87 5 9 J 2 17.65 23.03
DP 12.86 48.06 15 36.94
NDE 3.16 48.21 13.72 38.07
Trial 2
control 0.09 54.05 1 2 J2 33.63
BP 2 J 3 5 2 æ 19.04 27.74
DEt 6.7 51.83 15.78 32.38
DP 24.18 46.39 18.33 35.28
NDE 0.41 54.77 12.42 32.81
Average ± SD
control 0.6 ±0.8 50 ±5 15±3 35±2
BP 4 ± 2 54 ±2 15±5 30 ±4
DEt 9 ± 4 56 ±5 17 ± 1 28 ±7
DP 19±8 47 ± 1 17±2 36 ± 1
NDE 2 ± 2 51 ±5 13.1 ±0.9 35 ±4
A549
48h Apoptotic (%) 0 1  (%) G2/M (%) S (% )
Trial 1
control 1.36 54.85 0.04 45.11
BP 3.76 58.34 6.63 35.03
DEt 17.32 52.75 0 47.25
DP 43.1 54.18 10.17 15.65
NDE 2 4 9 58.75 0.06 41.19
Trial 2
control 33.99 66.01 0 33.99
BP 8.11 54.85 13.19 31.96
DEt 11.9 51.47 0 48.53
DP 31.98 52.02 15.28 32.7
NDE 0.16 64.23 9.03 26.74
Average ± SD
control 20 ±20 60 ±8 0.02 ± 0.03 40 ±8
BP 6 ± 3 57 ±2 10 ±5 34 ±2
DEt 15±4 52.1 ±0.9 0 47.9 ± 0.9
DP 38 ±8 53 ±2 13 ±4 20± 10
NDE 1 ±2 61±4 5 ± 6 30± 10
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DU145
24h Apoptotic (%) G IC ^ G2/M (%) S (% )
Trial 1
control 4.17 44.02 19.94 36.04
DB 14.82 52.3 2 T 2 8 20.42
DE 0.64 44.56 8.42 47.02
4TB 11.94 55.76 14.26 29.99
Trial 2
control 0.32 37.42 19.14 43.44
DB 3 4 3 54.85 9.87 35.28
DE 0.89 57.78 20.58 21.63
4TB 15.22 63.56 12.42 24.02
Average ± SD
control 2 ± 3 41+5 19.5+0.6 40 + 5
DB 9 + 8 54 + 2 20+10 30+10
DE 0.8 + 0.2 51+9 15+9 30 + 20
4TB 14 + 2 60 + 6 13 + I 27 + 4
DU 145
48h Apoptotic (%) G IC ^ G2/M (%) S (% )
Trial 1
control 0.81 53.61 15.52 30.87
DB 16.3 63.98 11.79 24.24
DE 1.24 55.74 15.68 28.58
4TB 3.92 57.67 13.06 29.27
Trial 2
control 1.57 47.76 14.51 37.74
DB 30.79 61.34 12.32 26.34
DE 19.09 52.66 19.15 28.2
4TB 10.58 52.28 17.52 30.2
Average ± SD
control 1.2+ 0.5 51+4 15.0 + 0.7 34 + 5
DB 20+ 10 63+2 12.1+0.4 25+1
DE 10 + 10 54 + 2 17 + 2 28.4 + 0.3
4TB 7 + 5 55+4 15+3 29.7 + 0.7
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DU-145
24h Apoptotic (%) G1 (%) G2/M (%) S (% )
Trial 1
control 0.51 41.12 18.8 40.08
BP 3.16 49.33 18.48 32.19
DEt 4.56 47.57 14.03 38.4
DP 12.67 53.79 18.66 27.55
NDE 3.66 5 1 2 6 16.45 30.29
Trial 2
control 0.73 45.51 19.27 35.22
BP 1 43.07 16.35 40.59
DEt 2.69 44.49 17.02 38.49
DP 7.73 42.24 18.18 39.58
NDE 4.69 50.01 4.11 45.88
Average ± SD
control 0.6 ±0.2 43 ±3 19.0 ±0.3 3 8 ± 3
BP 2 ± 2 46 ±4 17 ±2 36 ±6
DEt 4±  1 46 ±2 16±2 38.45 ±0.06
DP 10±3 48 ±8 18.4 ±0.3 34 ±9
NDE 4.2 ± 0.7 52 ±2 10±9 40± 10
DU-145
48h Apoptotic (%) G1 (%) G2/M (%) S(%)
Trial 1
control 1.57 48.42 19.63 31.95
BP 3.41 43.72 21.89 34.39
DEt 6.49 45.86 19.87 34.27
DP 31.68 49.03 16.17 34.8
NDE 20.21 42.44 13.64 43.92
Trial 2
control 0.98 53.4 0 46.6
BP 3.03 44.56 16.85 38.58
DEt 4.38 41.43 5.77 52.79
DP 14.97 46.97 14.09 38.95
NDE 6.02 4833 19.22 32.45
Average ± SD
control 1.3 ±0.4 51 ±4 10 ± 10 40 ± 10
BP 3.2 ±0.3 44.1 ±0.6 19 ±4 36 ±3
DEt 5 ±2 44 ±3 10 ± 10 40 ± 10
DP 20 ± 10 48 ± 1 15 ± 1 38 ±3
NDE 10 ± 10 45 ±4 16 ±4 38 ±8
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MCF-7
24h Apoptotic (%) G2/M (%) S (% )
Trial 1
control 1.06 41.09 12.43 46.48
DB 2 3 9 44.31 24.48 31.22
DE 1.67 43.6 24.77 31.62
4TB 1.4 47.51 16.34 36.15
Trial 2
control 1.58 34.80 24.12 41.08
DB 6.57 42.52 24.78 32.7
DE 3.02 47.36 18.46 34.18
4TB 3.03 37.75 19.91 42.35
Average ± SD
control 13+0.4 40 + 4 . 18 + 8 44 + 4
DB 4 + 3 43 + 1 25+4 32+1
DE 2+1 46 + 3 22+4 33 + 2
4TB 2+1 43+7 18 + 3 39 + 4
MCF-7
48h Apoptotic (%) G1 (%) G2/M (%) S (% )
Trial 1
control 0.60 52.57 11.80 35.63
DB 2.81 52.72 8.96 38.32
DE 6.55 39.84 2 3 3 36.87
4TB 1.87 54.79 9.64 35.57
Trial 2
control 0.73 52.15 13.03 34.82
DB 5.44 44.4 15.77 39.82
DE 9.04 49.8 26.95 23.25
4TB 0.93 5 3 3 14.07 32.13
Average ± SD
control 0.67 + 0.09 52.4 + 0.3 12.4 + 0.9 35.2 + 0.6
DB 4 + 2 49 +6 12.4 + 5 39.1+0.6
DE 8 + 2 45 + 7 25 + 3 30+10
4TB 1.4+ 0.7 54.3 + 0.7 12 + 3 34 + 2
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MDA-MB-435
24h ^ Apoptotic (%) Gl(%) G2/M(%) S(%)
Trial 1
control 5.95 23.8 27.07 49.12
DB 12 18.47 39.01 42.53
DE 0.15 15.29 17.47 67.24
4TB 0.38 18.42 20.49 61.08
Trial 2
control 0.7 30.42 20.32 49.26
DB 12.51 30.66 0 69.34
DE 1.05 35.63 20.71 43.65
4TB 7.05 32.69 20.39 46.92
Average ± SD
control 3 + 4 27 + 5 24 + 5 49.2 + 0.1
DB 12.3+0.4 25 + 9 20 + 30 60 + 20
DE 0.6 ±0.6 30+10 19 + 2 60 + 20
4TB 4 + 5 30 + 10 20.4 + 0.1 50+10
MDA-MB-435
48h Apoptotic (%) G1 (%) G2/M (%) Sf%)
Trial 1
control 0.24 51.10 19.43 29.47
DB 11.65 39.89 20.37 39.74
DE 2.4 39.46 17.48 43.06
4TB 0.81 42.06 16.41 41.53
Trial 2
control 0.06 39.38 20.47 40.15
DB 18.32 36.44 16.36 47.2
DE 0.66 30.44 19.08 50.48
4TB 0.58 37.3 19.03 43.67
Average ± SD
control 0.2+ 0.1 45 + 8 20.0 + 0.7 35 + 8
DB 15 + 5 38+2 18 + 3 43+5
DE 2+1 35+6 18+1 47 + 5
4TB 0.7 + 0.2 40 + 3 18 + 2 43+2
89
R ep ro d u ced  with p erm issio n  o f  th e  copyrigh t ow n er. Further reproduction  prohibited w ithout p erm ission .
MDA-MB-435
24h Apoptotic (%) G1 (%) G 2 M (% ) S(% 9
Trial 1
control 1.8 28.17 24.88 46.95
BP 2 j T 13.15 55.53 31.32
DEt 1.8 34.4 29.77 35.83
DP 47.62 19.72 3 5 3 5 44.93
NDE 3.21 16.96 48.05 34.99
Trial 2
control 0.53 32.58 33.73 33.69
BP 3.35 22.95 45.02 32.02
DEt 0.53 29.14 30.24 40.61
DP 11.86 2 3 3 2 20.00 56.69
NDE 27.84 30.08 53.17 16.75
Average ± SD
control 1.2 ±0.9 30 ±3 29 ±6 40 ±9
BP 2.9 ±0.6 18±7 50 ±7 31.7±0.5
DEt 1.2 ±0.9 32 ± 4 30.0 ±0.3 38 ±3
DP 30 ±30 2 2 ± 3 30± 10 51±8
NDE 20 ±20 24 ±9 51 ±4 30± 10
MDA-MB-435 ,
48h Apoptotic (%) G l ^ O G2/M (%) S (% )
Trial 1
control 14.83 32.21 30.91 36.88
BP 20.37 26.61 44.16 29.23
DEt 22.63 37.99 27.69 34.32
DP 20.7 50.63 0 49.37
NDE 67.78 51.61 36.17 12.21
Trial 2
control 25.14 47.27 17.70 35.02
BP 19.59 33.73 56.57 9.70
DEt 8.90 40.16 19.02 40.82
DP 22.65 69.30 30.70 0.00
NDE 48.60 10.71 50.32 38.97
Average ± SD
control 20 ±7 40± 10 24±9 36 ± 1
BP 20.0 ±0.6 30 ±5 50 ±9 20 ± 10
DEt 20 ±10 39 ±2 23 ±6 38±5
DP 22± 1 60 ± 10 20 ±20 30 ±30
NDE 60 ± 10 30 ±30 40 ± 10 30 ±20
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MDA-MB-231
24h Apoptotic (%) G1 (%) G2/M (%) S(%)
Trial 1 control 1.54 24.1 2736 48.54
DB 1.74 19.81 29.68 50.51
Trial 2
control 0J3 20.38 27.25 52.37
DE 10.66 21.46 23.59 54.96
4TB 12.14 19.99 36.92 43.09
Trial 3
control 1.25 33.19 23.15 43.66
DB 1.86 20.41 37.83 41.75
DE 16.89 17.9 26.88 55.23
4TB 12.76 25.73 33.7 40.58
Average ± SD
control 1.0+ 0.6 26 + 7 26 + 2 48+4
DB 1.8 + 0.1 20.1+0.4 34+6 46+ 6
DE 14 + 4 20 + 3 25+2 55.1+0.2
4TB 12.5 + 0.4 23±4 35+2 42 + 2
MDA-MB-231
48h Apoptotic (%) G1 (%) G2/M (%) S(%)
Trial 1 control 10.51 53.13 18.56 28.31
DB 19.94 42.31 28.19 29.5
Trial 2
control 4.38 35.84 21.58 42.59
DE 36J2 35.17 24.69 40.14
4TB 13.86 34.87 24.46 40.67
Trial 3
control 0.77 52.1 17.03 30.87
DB 2.25 43.01 22.64 34.35
DE 22.6 22.64 30.23 47.13
4TB 3.4 41.15 24.68 34.17
Average ± SD
control 5+5 50 + 9.70 19 + 2 34 + 8
DB 10+10 42.7 ±0.5 25 + 4 32 + 3
DE 30+ 10 29+9 27 + 4 44 + 5
4TB 9 + 7 38+4 24.6 + 0.2 37 + 5
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UNLV Cancer Institute 
Flew Cytometry Lab
T  IVDAIÆ435 070207.001
MDAMB435 24hr after Ihr treatment with Cisplatin
and analogs, AnnexinV/PI assay, 070207 VV
Tes,
CO o
FL1+I
NCAMB435 070207.007
10' 10‘ 10" 
FL1+I
kCAIvGIOS 070207.010
FL1-H
MDAIÆ435 070207.004
1 ■ ■ É 0 "
:
.................I| "T-m-niii
10^
mon
M>A1ve435 070207.013
FL1-W
Sample ID: 435-control-unstalned 
Acquisition Date: 02-Jul-07
Quad Events I Total
UL 138 1.38
UR 6 0.06
LL 9846 98.46
LR 10 0.10
Sample ID: 435-oontrol-Ann/PI 
Acquisition Date: 02-Jul-07
Quad Events % Total
UL 35 0.35
UR 211 2.11
LL 9296 92.96
LR 458 4.58
Sample ID: 435-328uM CIs-Ann/P 
Acquisition Date: 02-Jul-07
Quad Events % Total
UL 53 0.53
UR 489 4.89
LL 8988 89.88
LR 470 4.70
Sample ID: 435-20.3uM BP-Ann/P 
Acquisition Date: 02-Jul-07
Quad Events I Total
UL 61 0.61
UR 487 4.87
LL 9053 90.53
LR 399 3.99
Sample ID: 435-2.4uM 4TB-Ann/P 
Acquisition Date: 02-Jul-07
Quad Events I Total
UL 2 4 0 .2 4
UR 379 3.79
LL 9123 91.23
LR 474 4.74
1VDAMB435 070207.001o
o
FL1-H
I
M)AkB435 070207.004
FL1-H
IVOAIVB435 070207.007
FL1-H
IVOANC435 070207.010
FL1-H
tvDAIVG435 070207.013o
FL1-H
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KOAMB435 070207.016
Sam ple ID: 435-7.6uM  DEt-Ann/P 
Acquisition Date: 02-Jul-07
Quad Events % Total
UL
UR
LL
LR
510 5.10
2492 24.92
5547 55.47
1451 14.51
M)ArvB435 070207.016
0.......1.... 1,'to" 10' 10“^ 10'^  10^
FL1-H
IVDAIVB435 070207.019
IVDAtvB435 070207.022
Sam ple ID: 435-2.2uM DP-Ann/P 
Acquisition Date: 02-Jul-07
Quad Events % Total
UL 2592 25.92
UR 4184 41.84
LL 2302 23.02
LR 922 9.22
Sam ple ID: 435-2.5uM  DB-Ann/P 
Acquisition Date: 02-Jul-07
Quad Events % Total
10' 10‘ 10'' 
FL1-H
UL 2591 25.91
UR 4250 42.50
LL 1965 19.65
LR 1194 11.94
M3 AIVB435 070207.019
o r™r
MDAIÆ435 070207.022
o
FL1-H
M3AIVE435 070207.025
M3AIVB435 070207.028
Sam ple ID: 435-3.3uM DE-Ann/P 
Acquisition Date: 02-Jul-07
Quad Events % Total
UL 48 0.48
UR 398 3.98
LL 9283 92.83
LR 271 2.71
Sam ple ID: 435-3.SuM NDE-Ann/P 
Acquisition Date: 02-Jui-07
Quad Events I Total
UL 300 3.00
UR 2656 26.56
LL 5525 55.25
LR 1519 15.19
<=IVDA|VB435 070207.025
o
FL1-H
M)AtvB435 070207.028
n'""i i'...10" 10' 10^  10^  10< 
FL1-H
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UNLV Cancer Institut; 
Flow Cytometry Lab
MDAMB435 48hr after Ihr treatment with Cisplatin
and analogs, AnnexinV/PI assay, 070307 VV
IvDAIvBISS 070307.011
Sample ID: 435-unstalned 
Acquisition Date: 03-Jui-07
Quad Events ) Total
FL1-H
UL 364 3.64
UR 2 0.02
LL 9634 96.34
LR 0 0.00
IVDAIVB435 070307.011
FL1-H
kOAtvC435 070307.012
FL141
IVDAIVE435 070307.013
IVDAIVB435 070307.014
10® 10’ ' 10^  io^  10‘*
FL1-H
Sam ple ID: 435-control 
Acquisition Date: 03-Jul-07
IVDAIVB435 070307.012
Quad Events I Total
UL 114 1.14
UR 550 5.50
LL 9221 92.21
LR 115 1.15
Sam ple ID: 435-Cls 328uM 
Acquisition Date: 03-JuF07
Quad Events % Total
UL 203 2.03
UR 991 9.91
LL 8757 87.57
LR 49 0.49
Sam ple ID: 435-BP 20.3ulV 
Acquisition Date: 03-Jul-07
Quad Events I Total
UL 214 2.14
UR 1732 17.32
LL 7269 72.69
LR 785 7.85
V
III 11 mu
FL1-H
I
1vt)ANB435070307.013
o
FL1-H
M>Alve435070307.014
=
J
FL1-H
kt)AtvB435 070307.016
Sam ple ID: 435-DEt 3.8uM 
Acquisition Date: 03-Jul-07
Quad Events j Total
UL 267 2.67
UR 917 9.17
LL 8634 86.34
LR 182 1.82
M)Alve435070307.016
I
FL1-H
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M>A^e^35 070307.016
1 0 '  10 ' -  10 "  
FL1-H
Sample ID: 435-DEt 3.8uM 
Acquisition Date: 03-Jul-07
Quad Events I Total
UL 60 0.60
UR 993 9.93
LL 8435 84.35
LR 512 5.12
M)A1ve435 070307.016
FL1-H
1vOAtvE435 070307.017
Sample ID: 435-DP 2.2uM 
Acquisition Date: 03-Jul-07
Quad Events % Total
UL 1978 19.78
UR 2504 25.04
LL 2642 26.42
LR 2876 28.76
M>Ahe435 070307.017
mur
FL1-H
FL1-H
M>AlvB435 070307.020
Sample ID: 435-NDE 7.6uA 
Acquisition Date: 03-Jul-07
Quad Events I Total
FL1-H
UL 1004 10.04
UR 2313 23.13
LL 5704 57.04
LR 979 9.79
M)AlvB435 070307.020
FL1-H
M)AfvB435 070307.020
Sample ID: 435-NDE 7.6ul\ 
Acquisition Date: 03-Jul-07
Quad Events I Total
UL 1004 10.04
UR 2313 23.13
LL 5704 57.04
LR 979 9.79
.MDAIVB435 070307.020
FL1-H
IVDANS435 070307.020
FL1-H
Sample ID: 435-NDE 7.6ul\ 
Acquisition Date: 03-Jul-07
Quad Events % Total
UL
UR
LL
LR
114
1218
5080
3588
1.14
12.18
50.80
35.88
MDANG435 070307.020o
o
FL1-H
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UNLV Genomics Core 
Flow Cytometry Lab
MDAMB435 24hr after Ihr treatment with Cisplatin
and analogs, AnnexinV/PI assay, 072307 VV
IVDA1Æ435 070307.011
10' 10^  10" 
FL1-H
W>AMB435072307.012
FL1+I
MDAMB435 072307.014
MDAIVE435 072307.015
10° 10'
„  '""1. '   ..........0^" ml m^  iftJ ini10^
I/ , ' ' ' III" ! _ I r r n iii
FL1-H
10^  10" 10^  
FL1-H
kDAIVB435 072307.010
FL -H
Sample ID: 435-unstalned 
Acquisition Date: 03-Jul-07
Quad Events % Total
UL 364 3.64
UR 2 0.02
LL 9634 96.34
LR 0 0.00
Sample ID: 435-control
Acquisition Date: 23-Jul-07
Quad Events % Total
UL 1314 13.14
UR 839 8.39
LL 7664 76.64
LR 183 1.83
Sample ID. 435-DEt 3.8uM
Acquisition Date: 23-Jul-07
Quad Events % Total
UL 1600 16.00
UR 1523 15.23
LL 6391 63.91
LR 486 4.86
Sample! ID: 435-1DB 2.5uM
Acquisition Date: 23-Jul-07
Quad Events % Total
UL 2122 21.22
UR 3808 38.08
LL 2050 20.50
LR 2020 20.20
Sample ID: 435-NDE 7.6uM
Acquisition Date: 23-JUI-07
Quad IEvents % Total
UL 1138 11.38
UR 2876 28.76
LL 5070 50.70
LR 916 9.16
MDAIVB435 070307.011
o iiiinr i iiiiiii 111111^
FL1-H
IVDAMB435 072307.012
MDANG435 072307.014
NOANC435 072307.015
FL1-H
M)AkB435 072307.016o
o
FL1-H
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IVDAIVB435 072307.017
o - |  , ,  ........... .......... ...
lo" 10’ lO'^  10^  10^
FL1+I
T  IVDAMB435 072307.018
■nnf
10" 10' 10‘ 10" 10^  
F L I+ t
TT IÆIANC435 072307.019
o  f
IVDAIVB435 072307.020
Û...........■ 1 • ■ ™ i ',  ' " ......1
0" 1 0 ' 10"^ 10'^  10
FL1-H
Sam ple  ID: 435-4TB 2.4uM  
A cquis ition Date; 23-Ju i-07
Quad Events % Totai
UL 162 1.62
UR 1493 14.93
LL 6485 64.85
LR 1860 18.60
Sam pie iD: 435- D P2.2UM
Acqu isition  Date: 23-Ju l-07
Quad Events % Totai
UL 2078 20.78
UR 3535 35.35
LL 2286 22.86
LR 2101 21.01
Sam pie iD: 435- D E 3 .3 u M
A cquisition Date: 23-Ju i-07
Quad Events % Total
UL 1027 10.27
UR 1291 12.91
LL 7086 70.86
LR 596 5.96
Sam pie ID: 435-BP 20.3uiV 
A cqu is ition  Date: 23-Ju i-07
Quad Events I Totai
UL 396 3.96
UR 1111 11.11
LL 8064 80.64
LR 429 4.29
a
MDAfÆ435 072307.017o
o
FL1-H
IVDANG435 072307.018
FL1-H
■5
MDAIVB435 072307.019c
o pmi
FL1-H
,M>AIVB435 072307.020o
FL1-H
M>AIVB435 072307.021
"lo^  10 ' '"""13  ’d10*^ 10-^  10^  
FL1-H
Sam pie ID: 435-C is 328uM 
A cquis ition Date: 23-Ju l-07
Quad Events ) Tota i
UL 99 0.99
UR 1064 10.64
LL 7378 73.78
LR 1459 14.59
IVDArvB435 072307.021
o
FL1-H
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UNLV Genomics Core 
Ftaiv Cytometrv Lab
MDAMB435 48hr after Ihr treatment with Cisplatin
and analogs, AnnexinV/PI assay, 072407 VV
M5AIVE435 072407.025
...10' 10" 10 
FL1+I
rvDAtvB435 072407.026
FL1-H
Sam ple  ID: 435-unsta lned 
A cquis ition Date; 24-Jul-07
Quad Events % Total
UL 125 1.25
UR 4 0.04
LL 9868 98.68
LR 3 0.03
S am ple  ID: 435-contro l 
Acqu is ition  Date: 24-Ju l-07
Quad Events %  Total
UL 320 3.20
UR 788 7.88
LL 8710 87.10
LR 182 1.82
M )A tÆ 435  072407.025
FL1-H
J
tvDA(Æ 435 0 72407.026
FL1-H
IVDANC435 072407.027
1 0 '  10 "  
FL14I
T  tvDAkG435 072407.028
o  -,
FL14H
M )AM B435 072407.029
S am ple  ID: 435-D E t 3 .8uM 
A cqu is ition  Date: 24-Ju l-07
Quad Events % Total
UL 1285 12.85
UR 778 7.78
LL 7782 77.82
LR 155 1.55
S am ple ID: 435-D B 2.5U M  
A cqu is ition  Date: 24-Ju l-07
Quad Events I Total
UL 2134 21.34
UR 3506 35.06
LL 2317 23.17
LR 2043 20.43
Sam ple  ID: 435-NDE 7 .6u t 
Acqu is ition  Date: 24-Ju l-07
Quad Events %  Total 
UL 2296 22.96
UR 1807 18.07
LL 5414 54.14
LR 483 4 .83
M)AIVB435 0 72407.027o
FL1-H
M5AIVB435 072407.028
o
FL1-H
I
IVDANB435 072407.029o
FL1-H
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NOAIVB435 072407.030
Sam ple ID: 435-4TB 2.4uM  
Acqu is ition  Date; 24-Jul-07
Quad Events % Totai
UL 135 1.35
UR 556 5.56
LL 8761 87.61
LR 548 5.48
M)AIVB435 072407.030
10' 10^  10’' 
FL1-H
FL1-H
MDAIVB435 072407.031
f ' r iftiiif I I I l i m n  I i n im
FL -H
Sam ple  ID: 435-D P 2 .2uM 
A cqu is ition  Date: 24-Jui-07
Quad Events I Totai
UL 2920 29.20
UR 3927 39.27
LL 1841 18.41
LR 1312 13.12
<s
IVDAIVB435 072407.031
o
IVDAIVE435 072407.032
-  -n ''"""I,............io" 10' lO'^
FL1-H
MDAfyB435 072407 .033
FL1-H
Sam ple  ID: 435 -D E 3 .3uM  
Acquisition Date: 24-Jui-07
Quad Events p Total
UL 865 8.65
UR 808 8.08
LL 8219 82.19
LR 108 1.08
Sam ple  ID: 435-BP 20.3ul\/ 
Acqu is ition  Date: 24-Jul-07
Quad Events I Total
UL 1556 15.56
UR 2956 29.56
LL 5041 50.41
LR 447 4.47
M>ArvB435 072407.032
o
FL1-H
,IVDAkG435 072407.033
FL1-H
IVDAIVB435 072407.034
10' 10'- 10’' lO’
FL1-H
S am ple ID: 435-C is 328uM 
Acqu is ition  Date: 24-Jul-07
Quad Events ) Total
UL 106 1,06
UR 421 4.21
LL 9052 90.52
LR 421 4.21
i
MDA1VB435 072407.034
FL1-H
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MICROSCOPY DATA
MCF-7 48 hrs post 1 hr tx
Trial 1
Drug % Apoptosis % Necrosis
control 2.3 ±1.1 0.4 ±0.4
BP 6.0 ±3.0 4.7 ±3.2
4TB 4.7 ±1.0 1.0 ±0.9
DB 5.6 ±4.6 2.2 ±1.9
Trial 2
Drug % Apoptosis % Necrosis
control 1.3 ±1.2 0.1 ±0.2
BP 9.2 ±5.0 9.7 ±11.9
4TB 3.0 ±1.8 1.0 ±0.4
DB 13.7 ±2.7 3.5 ±3.6
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APPENDIX IV
STUDENT’S T-TEST DATA
EC50 values (M)
MDA-MB-435 MDA-MB-231 MCF-7
cisplatin 2.3E-04
3.5E-04
3.7E-04
3.5E-04
2.6E-04
3.0E-04
3.6E-04
2.7E-04
3.4E-04
3.2E-04
3.6E-04
3.2E-04
2.9E-04
BP 1.9E-05
2.1E-05
2.1E-05
2.1E-05
5.9E-05
2.4E-05
4TB 1.7E-06
3.1E-06
3.4E-06
4.8E-06
DEt 4.8E-06
2.9E-06
DP 2.2E-06
8.5E-07
2.2E-06
DB 2.3E-06
2.7E-06
7.5E-07
2.0E-06
5.9E-06
6.9E-06
NDE 9.3E-06
3.8E-06
6.0E-06
DE 4.0E-06
2.6E-06
7.0E-06
6.2E-06
3.3E-05
3.4E-05
2.8E-05
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EC50 values
A549 D U -145 DC4 DB46
cisplatin 8.5E-04
8.5E-04
6.1E-04
3.7E-04
BP 6.9E-05
3.8E-05
4TB 9.9E-05
4.8E-05
4.0E-06
1.6E-06
4.0E-06
3.2E-06
4.5E-06
DEt 1.9E-05
1.9E-05
DP 2.6E-05
1.5E-05
2.6E-06
2.7E-06
DB 8.9E-06
8.1E-06
2.3E-06
2.7E-06
1.6E-06
2.2E-06
2.1E-06
8.4E-07
NDE 2.4E-05
2.8E-05
DE 2.8E-05
2.1E-05
2.3E-05
2.1E-05
1.9E-06
1.9E-06
1.5E-05
5.8E-06
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Values from Student's t-test
MDA-MB-
435
MDA-MB- 
2 3 1 MCF-7 A549 DU-145
CIS,BP 0.000029 0.000029 0.0038 0.034
cis,4TB 0.000022 0.000023 0.038
cis,Det 0.000022 0.030
cis, DP 0.000022 0.0034 0.028
ciSjDB 0.000022 0.000023 0.0013 0.0033 0.028
cis, NDE 0.000022 0.030
cis, DE 0.000022 0.000024 0.016 0.0034 0.030
BP,4TB 0.0017 0.00077 0.28
BP,Det 0.0027 0.078
BP,DP 0.0020 0.040
BP, DB 0.00098 0.00050 0.090 0.040
BP, NDE 0.0030 0.11
BP, DE 0.0019 0.00035 0.33 0.090
Values from Student's t-test
MDA-
MB-435
MDA- 
MB-231 MCF-7 A549 DU-145 DC4 DB46
4TB,Det 0.18 0.083
4TB,DP 0.24 0.054
4TB,DB 0.46 0.047 0.054 0.12 0.061
4TB,NDE 0.060 0.10
4TB,DE 0.23 0.040 0.091 0.12 0.14
Det,DP 0.12 0.000051
Det,DB 0.16 0.00011
Det, NDE 0.13 0.033
Det, DE 0.36 0.066
DP,DB 0.13 0.082 0.32
DP,NDE 0.046 0.0035
DP,DE 0.11 0.29 0.0021
DB,NDE 0.067 0.0035
DB,DE 0.19 0.0091 0.0018 0.02 0.0022 0.49 0.10
NDE,DE 0.10 0.11
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Values from Student's t-test
CDDP BP 4TB DEt
A549,DU145 0.046
A549, MCF7 0.0074
A549,435 0.028
A549,231 0.034
A549,DC4
A549,DB46
DU145, MCF7 0.13 0.33
DU145,435 0.19 0.082 0.054 0.0020
DU145,231 0.20 0.085 0.056
DU145,DC4 0.11
DU145,DB46 0.056
MCF7,435 0.41 0.17
MCF7,231 0.18 0.18
MCF7,DC4
MCF7,DB46
MDA-MB435,MB231 OJ* 023 0.11
435,DC4 0.25
435,DB46 0.14
231,DC4 0.23
231,DB46 0.40
DC4,DB46 0.29
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Values from Student's t-test
DP DB NDE DE
A549,DU145 0.042 0.0027 0.30
A549, MCF7 0.041 0.13
A549,435 0.091 0.0029 0.015
A549,231 0.0051 0.020
A549,DC4 0.0025 0.013
A549,DB46 0.0057 0.065
DU 145, MCF7 0.010 0.013
DU145,435 0.096 0.47 0.0057 0.0030
DU145,231 0.11 0.0036
DU145,DC4 0.098 0.0020
DU145,DB46 0.13 0.061
MCF7,435 0.010 0.0010
MCF7,231 0.012 0.0023
MCF7,DC4 0.0081 0.0021
MCF7,DB46 0.014 0.044
MDA-MB-435,231 0.11 0.028
435,DC4 0.11 0.094
435,DB46 0.14 0.13
231,DC4 0.25 0.0031
231,DB46 0.45 0.25
DC4,DB46 0.31 0.10
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MDA-MB-435 Annexin V data
Apoptotic (%) Apoptotic (%) Necrotic (%) Necrotic (%)
Control 10.22 0.35 13.14
CDDP 25.23 0.53 0.99
BP 8.86 15.4 0.61 3.96
4TB 8^3 33.53 0.24 1.62
24 h DEt 26.39 20.09 15.88 16
DP 51.06 56.36 25.92 20.78
DB 54.44 58.28 25.91 2T22
NDE 325 37.92 9.3 11.38
DE 6.69 18.87 0.48 10.27
Control 6.65 9.7 1.14 3.2
CDDP 10.4 8.42 2.03 1.06
BP 25.17 34.03 2.14 15.56
4TB 6.36 11.04 3.19 1.35
48h DEt 10.99 9.33 2.67 12.85
DP 53.8 52.39 19.78 292
DB 27.63 55.49 23.73 21.34
NDE 324% 229 10.04 22.96
DE 12.8 9.16 1.51 8.65
Values Irom t-test
24 h 48h
apoptosis necrosis apoptosis necrosis
con, CDDP 0.19 0.22 0.28 0.32
con,BP 0.21 0.28 0.02 0.21
con, 4TB 0.21 0.23 0.43 0.47
con, Det 0.03 0.14 0.19 0.20
con, DP 0.002 0.07 0.001 0.02
con, DB 0.001 0.07 0.07 0.003
con, NDE 0.007 0.32 0.03 0.08
con,DE 0.28 0.44 0.18 0.26
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MCF-7 fluorescent microscope results
Drug % Apoptosis % Apoptosis % Necrosis % Necrosis
control 2.3 1.3 0.4 0.1
BP 6 9.2 4.7 9.7
4TB 4.7 3 1 1
DB 5.6 13.7 2.2 3.5
Values from t-test
apoptosis necrosis
con, DB 0.10 0.03
con, 4TB 0.09 0.02
con BP 0.04 0.05
DB, 4TB 0.15 0.05
DB, BP 0.34 0.12
4TB, BP 0.09 0.07
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